Cell Transdifferentiation and Reprogramming in Disease Modeling: Insights into the Neuronal and Cardiac Disease Models and Current Translational Strategies

Rajkumar Singh Kalra 1,†,‡, Jaspreet Kaur Dhanjal 2,*,‡, Mriganko Das 3,‡, Birbal Singh 4 and Rajesh Naithani 5

Abstract: Cell transdifferentiation and reprogramming approaches in recent times have enabled the manipulation of cell fate by enrolling exogenous/artificial controls. The chemical/small molecule and regulatory components of transcription machinery serve as potential tools to execute cell transdifferentiation and have thereby uncovered new avenues for disease modeling and drug discovery. At the advanced stage, one can believe these methods can pave the way to develop efficient and sensitive gene therapy and regenerative medicine approaches. As we are beginning to learn about the utility of cell transdifferentiation and reprogramming, speculations about its applications in translational therapeutics are being largely anticipated. Although clinicians and researchers are endeavoring to scale these processes, we lack a comprehensive understanding of their mechanism(s), and the promises these offer for targeted and personalized therapeutics are scarce. In the present report, we endeavored to provide a detailed review of the original concept, methods and modalities enrolled in the field of cellular transdifferentiation and reprogramming. A special focus is given to the neuronal and cardiac systems/diseases towards scaling their utility in disease modeling and drug discovery.

Keywords: transdifferentiation; cell reprogramming; induced pluripotency; disease modeling; neuronal diseases; cardiac disease; regenerative medicine; therapeutic strategies

1. Introduction

The quenching of cell stemness as cell progressively proliferates and acquires a differentiated state was initially thought to be an irreversible mechanism [1]. The canonical design of a biological process such as cell differentiation has now largely been disproved in the light of emerging evidence about the cellular reprogramming and transdifferentiation mechanisms that potentiate conversion of a lineage-specific, differentiated cell into another/different lineage/cell type [2]. In the process of differentiation, a pluripotent stem cell systematically proliferates and undergoes the intermediate/progenitor and differentiated progenitor/multipotent stages before losing its plasticity and dividing terminally into the specialized/mature cells which constitute an organ or tissue [3]. Mechanistically, when a differentiated cell reverts to its parental lineage or less-differentiated cell to acquire a proliferative phenotype, the process is generally known as dedifferentiation, while...
transdifferentiation suggests the direct conversion of a differentiated cell type to another differentiated cell type without entering a pluripotent state. Therefore, transdifferentiation is often called direct cell reprogramming [3,4]. Both differentiation and transdifferentiation events can occur naturally [2]. In contrast, the process of cell reprogramming or induced pluripotency, which refers to the process of reverting specialized/differentiated cells to the induced pluripotent stem cells (iPSCs) state, is largely artificial [5] (Figure 1).

![Figure 1. Schematic diagram showing processes of differentiation, reprogramming, transdifferentiation (direct conversion), and dedifferentiation in determining the cells fate, while dedifferentiation represents a reverse step in this process. Model exhibiting the pluripotent stem cells differentiation to intermediate progenitor SCs, then to multipotent SCs/differentiated progenitors, and eventually to mature tissue-specific specialized cells. Reprogramming indicates reverting back a mature cell into induced pluripotent stem cells (may consist of an intermediate step/cell population) with the help of specific TFs and chemicals/small molecules. Transdifferentiation represents the direct conversion of a specialized mature cell into another cell type by the help of specific TFs and chemicals/small molecules. Cell reprogramming can be induced artificially by chemicals/small molecules or by expressing certain transcription factors (TFs), which reprogram a cell to enter an intermediate or pluripotent state [6] (Figure 1). Davies and Weintraub, in the earliest report in 1987, firstly demonstrated the ability of lineage-specific TFs to govern cell fate [7]. Murry et al., later in 1996, brilliantly showed that MyoD expression across different cell lines in vitro stimulates muscle-specific genes’ expression and may further convert these cells into myoblasts [8]. Accumulating evidence in the last three decades has significantly established...](image-url)
cellular reprogramming and transdifferentiation in mammals; however, events altering cell fate were also seen to occur naturally [9].

The pathological side of these processes is known in clinical practice, for instance in Barret’s metaplasia, Cdx2 activation transdifferentiates stratified squamous cells into epithelial cells, which potentiates esophagus carcinoma [10]. Earlier reports showed that the transdifferentiation of diverse cell types into myofibroblasts may cause fibrosis in the case of injury or chronic damage to the liver [11], kidney [12], and muscle [13], while a natural transdifferentiation mechanism can be seen in heart [14], liver [15], and in the lens regeneration process in axolotls [16]. Although such remarkable regeneration abilities produced by endogenous transdifferentiation are largely restricted to lower vertebrates, mammals exhibit limited features [9]. For instance, after injury, Lgr5+ led transdifferentiation induces the revival of the hair follicular cells in the inner ear, a rare feature that is exclusive to the neonatal stages. However, in the adults it fails to repair injury significantly [17].

Developments in this field have largely been fueled by investigations into these model organisms and their regenerative abilities, and from the accumulating knowledge on small molecules/chemicals and key cell fate-regulators. The latter includes key transcription factors that can instigate cellular reprogramming and transdifferentiation [18–22], which is largely seen as a promising therapeutic strategy in disease modeling [5,23–26]. In the following section, we review the role of diverse factors involved in cellular transdifferentiation towards regulating the cell fate in disease modeling.

2. Cell Transdifferentiation: An Overview

A recent development in transdifferentiation or direct lineage-reprogramming—where a cell converts into another cell type without crossing the pluripotent state—offered novel applications to produce functional cells/tissues in disease modeling [18]. Although several functional cell types, including cardiomyocytes, neurons, progenitor/stem cells, hepatic stem cells, hepatocytes, and blood/hematopoietic stem cells have been obtained from fibroblasts/other somatic cells in vitro using the TFs or chemical-mediated transdifferentiation approach, a greater focus of translational research on neural and cardiac cells has been evident.

2.1. TFs-Mediated Transdifferentiation and Scope in Disease Modeling

An increasing therapeutic focus in neural and cardiac research prompted a series of investigations in the area and led to significant progress being made in the field of in vitro and in vivo transdifferentiation. Multiple studies produced transdifferentiated cells that phenotypically resemble their natural counterparts and maintain prolonged functionality within the neural and cardiac tissues (Table 1).

2.1.1. TFs-Mediated Neural Stem/Progenitor Cell Transdifferentiation

A high prevalence of neurodegenerative diseases encouraged transdifferentiation strategies to regenerate neurons/neural networks in the central nervous system (CNS) and brain. By instigating in vivo transdifferentiation in the brain of an adult mouse, a report in 2013 first demonstrated a proof-of-principle of the mechanism. In this report, Torper and colleagues enrolled both resident cells, i.e., astrocytes, and transplanted cells, i.e., fibroblasts and astrocytes, as carrier cells, and performed delivery of Ascl1, Myt1l, and Brn2a TFs using a viral vector [27]. The adopted transgenic and transplantation approach comprehensively demonstrated ease at yielding specialized populations, including dopaminergic, and DA neurons. They suggested the suitability of astrocytes for neuron transdifferentiation considering their enriched and ubiquitous presence in the brain [27] (Figure 2).

In another report, Niu et al. adopted a lentiviral-based astrocyte-specific GFAP promoter system and transdifferentiated the target population into neuroblast cells in the mouse brain [28]. Of note, they found that a single TF-Sox2 was sufficient to transdifferentiate the target cells. Importantly, this strategy produced proliferative precursor cells, such as native neuroblasts, and called them induced adult neuroblasts (iANBs). They
enrolled BNTP and Noggin—neurogenic factors and VPA, VP—epigenetic modulator to further support iANBs maturation towards developing into electrophysiologically efficient, circuit-integrated mature neurons in vivo. Such iANBs-derived mature neurons were found to be associated with different subtypes yet mainly expressed calretinin [29]. They later carried out Sox2-mediated transdifferentiation of astrocytes to neuroblasts in spinal cord injury in another report [30]. In the case of spinal cord injury, the GFAP-lentiviral delivery system was seen to improve astrocyte proliferation in the region and to form a glial scar, yet it was later found to restrict axon regeneration [31]. However, in the in vivo systems, transdifferentiation efficiency in the adult brain was limited, as only 3–6% of astrocytes were transdifferentiated into iANBs. Additionally, iANB-derived GABAergic neurons were seen to form synapses with the native neuronal networks; however, their electrophysiological function could not be confirmed. Moreover, the extent of viral load as a vector was suggested to be disadvantageous for transdifferentiation efficiency, and the survival of transduced cells was also found to be a limitation towards scaling its utility for disease modeling (Table 1).

Taking two brain-injury cases—including stab-injured brain and Alzheimer’s disease (AD) brain tissue—another report enrolling NeuroD1 showed an efficient transdifferentiation of glia/astrocytes and NG2 cells into the functional and mature neurons in mouse brain. These mature neurons were locally integrated into the neural circuits and sustained survival for about 2 months [32]. It was promising to see that NeuroD1 has the potential to transdifferentiate astrocytes into the glutamatergic neurons in the human in vitro model; however, no data on behavioral rehabilitation were captured.

Moreover, the post-mitotic status of neurons makes it tougher to systematically acquire transdifferentiation in target cells. Rouaux and Arlotta, by taking Fefz2, i.e., a key corticofugal projection factor, used the utero electroporation method and performed transdifferentiation of the excitatory neurons in the cortex region of mouse brain [33]. They affirmed that a significant population of transdifferentiated cells retained these changes for about 4 weeks. Simultaneously, another report demonstrated similar results. In this report, De la Rossa and colleagues introduced Fefz2 in the brain cortex, yet they used the iontoporation and CreERT2 methods to stimulate the TF expression at different developmental stages [34]. Using specific promoters, they controlled TF expression in specific populations and effectively transdifferentiated L4 spiny neurons into L5B neurons that exhibited native phenotype, transcriptomic signature, axon character, and bidirectional signal connectivity (Table 1).

Recently, Qin et al. demonstrated the transdifferentiation of human fibroblast cells into DA-neuron-like cells by using a combination of protein factors and small molecules [35]. Their method exhibited efficient direct conversion, as 95% of yielded cells were TUJ1-positive, and the process did not include an intermediate neural stem/progenitor stage. In another recent report, Song et al., by using a doxycycline-inducible TFs system (carrying Ngn2, Ascl1, and Dbx2) in human pluripotent stem cells, performed the successful transdifferentiation of these cells into excitatory and inhibitory neurons, exhibiting an equivalent phenotype and molecular signature [36].

Although these studies still do not qualify directly for therapeutic applications or diseases modeling, they do demonstrate proof-of-principal that neurons with post-mitotic state can be transdifferentiated, and cell-to-cell conversion can be programmed. These reports decisively affirmed that TFs-mediated neural stem/progenitor cells’ transdifferentiation can critically shape its therapeutic applications, and utility in disease modeling, more specifically in neurodegenerative and age-related neuronal diseases.
Table 1. Transcriptional factor(s)(TFs)-induced transdifferentiation, mechanism of action, and outcomes in the CNS/brain and cardiac model systems.

| Disease Model          | Species/Tissue Source (Cell Type) | Transdifferentiated Cell (Converted) | Transdifferentiation Factors/TFs | Delivery/Vehicle | Efficiency | Results/Physiological Outcome | References |
|------------------------|-----------------------------------|-------------------------------------|----------------------------------|------------------|------------|-------------------------------|------------|
| CNS/Brain              | Mouse brain                       | Astrocyte, Fibroblast               | Induced neuron (iN)               | Mgt1l, Ascl1, Brn2a | Transduced in vitro/Doxycycline in drinking water/Lentiviral | 0.4% to 5.9% iNs in tissue | [27]        |
| CPN (Colossal projection neuron) | Corticofugal projection neuron (CFuPN) | Fezf2                               | Electroporation (in utero)/Plasmid DNA | 75.6% of Fezf2-expressing CPN (+ve for CFuPN marker) | Morphological change, gene and protein expression (until P3). Axon connectivity change (until E17.5) | [33]        |
| CNS/Brain              | Mouse brain                       | L4 neuron                           | L5B neuron                        | Fezf2            | Electroporation (in utero)/Plasmid DNA | 50% for Fezf2+ L4 and L5B neurons | Morphological change, gene and protein expression (until P1) | [34]        |
| CNS/Brain              | Mouse brain, Human cortical astrocytes | Astrocyte NG2 cell                  | Induced neuron (iN)               | NeuroD1          | Stereotactic (brain)/Retroviral | 41% of YFP+ cells expressed NG2; 23.2% of GFP+ cells were +ve for DCX | Transdifferentiated iANBs in tissue. Transdifferentiated mature neurons (+VNTP/Noggin or VPA) | [28,29] |
| Stab injury in AD      | Mouse brain, Human cortical astrocytes | Astrocyte NG2 cell                  | Induced neuron (iN)               | NeuroD1          | Stereotactic (brain)/Lentiviral | 90% | Transdifferentiated iN in tissue. Functional or behavioural data not acquired | [32]        |
| Spinal cord injury     | Mouse Spinal cord                 | Astrocyte                           | Induced adult neuroblast (iANB)   | Sox2             | Stereotactic (spinal cord)/Lentiviral | 3–6% were re-programmed by SOX2 | Transdifferentiated iANBs in tissue. Mature neurons (+VPA) synapses with resident neurons. Functional data not acquired | [30]        |
| Disease Model         | Species/Tissue | Source (Cell Type) | Transdifferentiated Cell (Converted) | Transdifferentiation Factors/TFs | Delivery/Vehicle | Efficiency | Results/Physiological Outcome                                                                 | References |
|----------------------|----------------|-------------------|-------------------------------------|---------------------------------|-----------------|-----------|-----------------------------------------------------------------------------------------------|------------|
| Freeze–thaw injury   | Rat            | Cardiac fibroblasts | Skeletal myofibers                  | MyoD                            | Intramyocardial/Adenovirus | 2–14%     | Produced myofibers (immature) in tissue                                                       | [8]        |
| Myocardial infarction| Mouse          | Cardiac fibroblast | Cardiomyocytes                      | GMT (Gata4, Mef2c, Tbx5)        | Intramyocardial/Retrovirus | 10–15%    | Reduced infarct size. Significant decrease in cardiac dysfunction                             | [37]       |
|                      |                | Cardiac fibroblast | Cardiomyocytes                      | GMT (Gata4, Mef2c, Tbx5)        | Intramyocardial/Retrovirus | 3–7%      | Cardiomyocytelike cells in fibrotic area. No physiological functional results                | [38]       |
|                      |                | Cardiac fibroblast | Cardiomyocytes                      | GHMT (Gata4, Hand2, Mef2c, Tbx5) | Intramyocardial/Retrovirus | ~7%       | Reduced infarct size. Significant decrease in cardiac dysfunction                             | [39]       |
|                      |                | Cardiac fibroblast | Cardiomyocytes                      | microRNAs 1, 133, 208 & 499     | Intramyocardial/Lentivirus   | 12–25%    | Fibroblast transdifferentiation into cardiomyocyte in the infarct spot/area. Moderate decrease in cardiac dysfunction | [40,41]   |
| Complete heart blockage | Pig         | Pacemaker cell-induced sinoatrial node cell | Tbx18                               | Percutaneous, to heart ven- tricle/Adenovirus | 24.5%          | Constituting a biological pacemaker. Improvement of bradycardia                           | [42]       |
|                      |                | Pacemaker cell-induced sinoatrial node cell | Tbx18                               | Intramyocardial/Adenovirus      | 9.2%            | Constituting a biological pacemaker. Improvement of bradycardia                            | [43]       |
2.1.2. TFs-Mediated Cardiomyocytes’ Transdifferentiation

Given the clinical prevalence and translational significance of cardiovascular disease [44], the scope of somatic cell transdifferentiation to cardiomyocytes (CMs) has been widely investigated. In one of the earliest reports, the researchers tried to revive an injured rat heart by instigating MyoD-mediated transdifferentiation of the heart fibroblasts into skeletal muscle cells [8]. Although the study involved the transfection of MyoD-expressing cells and embryonic-MHC, no data on the cell fusion or maturation (embryonic myofibroblasts into functional cells) and their integration with native cardiomyocytes were obtained. However, the presence of myofiber like cells in the cardiac microenvironment hinted at an incomplete maturation of the cells into a skeletal muscle phenotype. Furthermore, an elicited immune response against the adenoviral vector that was used in high-dose in the study was suggested to compromise the outcome (Figure 2). This earliest report in many ways advanced the field by providing initial experimental knowledge and by facilitating further attempts that enrolled multiple TFs that aimed to regenerate and obtain mature CMs. Consistent with this, two independent reports in 2012 adopted a similar strategy and endeavored to regenerate the myocardium post-myocardial infarction (MI) by transdifferentiating the heart fibroblasts into induced-CMs (iCMs) in mouse heart. Taking the *Gata4*, *Mef2c*, and *Tbx5* (GMT) transcription factors, Inagawa et al. and Qian et al. utilized a retroviral system to selectively transfect dividing cells to deliver it to the cardiac fibroblasts exclusively, avoiding post-mitotic CMs [37,38]. Qian and colleagues further validated the fibroblastic origin of iCMs, and the transdifferentiated cells shared similar features to native cells in terms of morphology, transcriptome, sarcomeric design, and electrical behavior. The iCMs acquired identical electrical stimulation function to ventricular CMs and significantly improved cardiac function, while no arrhythmias or cardiac death events were reported.

**Figure 2.** Schematic diagram showing processes of cardiac and neuronal transdifferentiation from a normal somatic cell. Transdifferentiation of somatic cell/fibroblast into cardiomyocytes is induced by certain combinations (listed) of cardiac-specific TFs or chemicals/small molecules (**left side**); while transdifferentiation of somatic cells, specifically of astrocytes, glia, or human mesenchymal stem cells (hMSCs), into mature neurons can be induced by certain combinations (listed) of specific TFs or chemicals/small molecules (**right side**). Both processes highlight translational and regenerative potential of transdifferentiation in disease modeling and drug discovery.
By estimate, the adopted strategy was found to transduce 4% of the fibroblasts in infarcted areas, out of which only 10–15% were found to be transdifferentiated, thus hinting at lesser transdifferentiation efficiency. This was even more evident in the investigation by Inagawa et al. where resulting iCMs largely lacked maturation. Christoforou and colleagues further showed that expression of *Myocd* and *Srf*—by itself or in combination with *Smarcd3* and *Mesp1*—can enhance the basal yet needed cardio-inducing impact of the known TFs *viz.* *Gata4*, *Ata4*, *Tbx5*, and *Mef2c* during direct cellular reprogramming [45]. Later, in 2017, by using a consortium of TFs (*Gata4*, *Tbx5*, *Mef2c*, *Myocd*, *Nkx2-5*) and microRNAs (miR-1 and miR-133a) they further successfully achieved the reprogramming of human dermal fibroblasts into iCM-like cells. Of note, enriched expression of cardiac-specific genes, activated myocardial and physiology-related pathways, and decreased levels of fibroblastic markers were evidently seen in these reprogrammed iCM-like cells [46].

Given the in vivo scenario, it was believed that transdifferentiation achieves better results in vivo than in vitro culture, probably due to a more native/homogenous microenvironment that effectively sustained cell survival and maturation [37,47]. These reports emphasized the role of the native microenvironment in achieving functionally mature transdifferentiated cells, which could enable the revival of injured tissue. Adopting a similar strategy and an additional TF-*Hand2*, Song et al. further aimed to improve the transdifferentiation efficiency [39]. This strategy indeed improved the iCM generation efficiency to 6.8% and also the cardiac function recovery after MI.

Moreover, another study also endeavored to achieve cell transdifferentiation after MI; however, it adopted a lentiviral approach including a cocktail of four micro-RNAs *viz.* miRNA 1, 133, 208, and 499 that have functions in CM development [41]. Another report from this group revealed that the electrical features of transdifferentiated iCMs subsets were comparable to the endogenous CMs, which was reflected in the moderately improved cardiac function [40]. However, a lesser efficiency of transdifferentiation and immature iCMs hinted at the limitations of the adopted strategy and stressed the need for process optimization. Further, Mathison et al., in 2017, using an adenoviral vector system expressing GMT cardiac TFs, directly transdifferentiated the fibroblast cells into cardiomyocytes [48]. These cells were found to improve cardiac function in the post-infarct rat hearts. These reports demonstrated effective transdifferentiation as affirmed by lineage tracing or adopted co-transduction strategies, and by validation of iCMs fibroblastic origin. However, it was believed that transdifferentiation efficiency could be improved further if this step were delayed after injury, as it could allow more fibroblasts migration to the infarct site [8] (Table 1).

### 2.2. Chemicals/Small Molecule-Mediated Transdifferentiation

Growing concerns on the safety of viral DNA integration (delivery vehicle/plasmid used in TFs-mediated transdifferentiation) and stochastic risk of oncogene potentiation, led many researchers to explore the utility of chemical/compounds or small molecules with a revised transdifferentiation efficiency. In this section, we review diverse approaches involving chemicals/small molecules for neural stem/progenitor and cardiac cells’ transdifferentiation (Table 1).

#### 2.2.1. Chemical/Small Molecule-Mediated Neural Stem/Progenitor Cell Transdifferentiation

Cheng et al., in 2014, were the first to use human urinary and mouse fibroblast cells and demonstrate the formation of fully chemical-induced neural progenitor cells (ciNPCs) by three small molecule cocktails that included CHIR99021 (GSK3 inhibitor), VPA (HDAC inhibitor), and Repsox (TGFβ inhibitor). They achieved the generation of ciNPCs under physiological hypoxic (5% O2) condition, using no expression of any exogenous TFs/genes [49]. An alternative cocktail including LiCl, NaB, and SB431542 or Li2CO3, TSA, and Tranilast small molecules exhibited similar efficacies of ciNPC generation when enrolled with inhibitors of HDAC, GSK3, and TGFβ signaling. These ciNPC exhibited
multipotent phenotypes and efficiently differentiated into different neural cell types in both in vitro and in vivo systems (Figure 2).

Similarly, using a cocktail of nine small molecules (M9), Zhang et al. further efficiently induced transdifferentiation into mice fibroblasts to produce neural stem cell-like cells (ciNSLCs) [50]. Initially, they enrolled three small molecules (LDN193189, A83-01, CHIR99021) and one growth factor (basic fibroblasts growth factor; bFGF) known to modulate epigenetic and neuro-generative signaling. On top of these three molecules, the other small molecules were assessed. Of note, Hh-Ag 1.5 and retinoic acid distinctly enriched Sox2+/Nestin+ cells and therefore these two chemicals were again included in the basal conditions to screen small molecules along with six chemicals. Interestingly, three chemicals, viz. Parnate, RG108, and SMER28, were further shown to improve the induction of Sox2+/Nestin+ cells, thereby establishing the M9 cocktail. They also highlighted the role of the Elk1 and Gli2 transcription factors, which function in MP-induced signaling and activate key neural genes that have specialized functions in determining the neural identity. Cortes-Medina et al., in 2019, by using a cocktail of I-BET151, forskolin, CHIR99021, Y-27632, RepSox, and dbcAMP small molecules, demonstrated neural transdifferentiation potential of human mesenchymal stem cells [51]. They also revealed that the addition of neurotrophic factors to the cocktail further increased the cells’ numbers significantly, and the cells exhibited a neuronlike morphology and the expression of neural markers (Tables 2 and 3).

### Table 2. List of cardiovascular diseases modeled with human iPSCs or ESCs.

| Disease Model for Cardiac Dysfunctions | Impacted/Mutated Genes |
|---------------------------------------|------------------------|
| Left ventricular noncompaction          | TBX20, GATA4            |
| Familial hypercholesterolemia          | LDLR, PCSK9             |
| Timothy syndrome                       | ACNA1C                 |
| Dilated cardiomyopathy                 | TTN, TNNT2, LMNA, DES  |
| Duchenne muscular dystrophy            | DMD                    |
| Arrhythmogenic right ventricular dysplasia | PKP2                   |
| Long-QT syndrome type 1                | KCNQ1                  |
| Jervell and Lange-Nielsen syndrome     | KCNQ1                  |
| Catecholaminergic polymorphic ventricular tachycardia type 1 | RYR2                   |
| Catecholaminergic polymorphic ventricular tachycardia type 2 | CASQ2                  |
| Brugada syndrome                       | SCN5A                  |
| Calcific aortic valve                  | NOTCH1                 |
| Williams–Beuren syndrome               | ELN                    |
| Familial pulmonary hypertension        | BMPR2                  |
| Barth syndrome                         | TAZ                    |
| Hypertrophic cardiomyopathy            | MYH7                   |
| Maturity-onset diabetes of the young type 2 | GCK                    |
| Insulin resistance                     | AKT2                   |
| Familial hypobetalipoproteinemia       | PCSK9                  |
| Long-QT syndrome type 2                | KCNH2                  |
| Long-QT syndrome type 3                | SCN5A                  |
| Tangier disease                        | ABCA1                  |
| Dyslipidemia                           | SORT1                  |
| Hypoinsulinemic hypoglycemia and hemihypertrophy | AKT2                  |
2.2.2. Chemical/Small Molecule-Mediated Neuronal Transdifferentiation

Using the full-chemical strategy, in 2015, two simultaneous reports successfully produced human and mouse neurons from their fibroblast cells [52,53]. Using Ascl1, i.e., a regulator of neuronal cell fate, Li et al. constituted a neural transdifferentiation system and screened small molecules that led to the finding of four molecules, viz. Forskolin, CHIR99021, ISX9, and SB431542, which promoted the Ascl1-mediated generation of neuronal cells from mouse fibroblasts [52]. Of note, a cocktail of four molecules was found to efficiently stimulate neuronal transdifferentiation and it was evident without Ascl1. They also identified an additional small molecule viz. 1-BET151 that strikingly improved the transdifferentiation efficiency (>90% TUJ1+). Later, since SB431542 activity was found to be negligible, the final cocktail constituted Forskolin, CHIR99021, ISX9, and 1-BET151. On the mechanistic side, they elucidated that 1-BET151, a BET family bromodomain inhibitor essentially suppresses fibroblast-specific genes, whereas ISX9, a neurogenesis inducer, activates neuron-specific transcriptional program [52]. In another report, Hu et al. tested CHIR99021, VPA, and Repsox (VCR) small molecules (earlier shown to generate ciNPCs from human, mouse, and somatic cells [49]) and postulated that this VCR cocktail with chemicals known to elicit the neurodifferentiation of neural progenitor cells can stimulate the transdifferentiation of human fibroblast cells into neural cells. Consistent with this, they found that Forskolin with VCR can partially induce a neural transdifferentiation activity in the human fibroblast. Besides these two molecules, they found that GO6983, SP600125, and Y-27632 can also efficiently promote neural transdifferentiation, which was validated by the presence of Tuji+ cells with a neuronlike phenotype [53]. Although the cocktail of above seven small molecules demonstrated a distinct transdifferentiation efficiency, the survival and maturation of the produced neurons remained largely compromised. It led them to enroll extra neurotropic factors viz. NT3, BDNF, and GDNF along with CHIR99021, Forskolin, Dorsomorphin, which improved the method and produced fully functional and mature neurons. This method was further employed to produce functional neurons from familial AD patients. In another report, Zhang et al. identified a chemical cocktail that can efficiently transdifferentiate human astrocytes into neural cells [54]. Their screening involved a pool of 20 small molecules, compounds of which were earlier found to inhibit glial related signaling and to activate neural-related pathways/programs partly by modulating epigenetic programming. Extensive screening eventually led them to identify a cocktail of nine small molecules viz. SB431542, LDN193189, TTNPB, CHIR99021, Thiazovivin, DAPT, VPA, purmorphamine, and smootherned agonist that, in a stepwise manner, can efficiently transdifferentiate astrocytes into neurons. Of note, these transdifferentiated neurons sustained survival for about five months in vitro and constituted multiple functionally viable synaptic networks (Tables 2 and 3).

Obtaining human cells and stem cells is a practical impediment. Given the non-invasive source of multiple types of cells, urine can be obtained from patients of any age. Urine cell-derived competent cells have emerged as a major tool for research given its therapeutic importance [55]. Xu et al. demonstrated direct transdifferentiation of human urine cells to neurons using a seven small molecule cocktail (CHIR99021, A8301, Y-27632, TTNPB, Forskolin, VPA, NaB) [56]. The transdifferentiated neurons exhibited a mature neuronlike phenotype and molecular signature as validated by the expression of neuronal markers. Further, Qin et al. used a combination of small molecules and protein factors and successfully performed transdifferentiation of human fibroblasts into neuronlike cells without passing through a neural stem/progenitor intermediate stage [35]. Although these reports showed efficient neuronal transdifferentiation from various cell types, the underlying molecular mechanism of these processes warrants further investigation.

2.2.3. Other Chemical/Small Molecule-Mediated Transdifferentiation

Besides the cardiac and neuronal transdifferentiated studies, a few attempts have been made to obtain transdifferentiated pancreatic β-cell, endodermal, and liver progenitor cells [47,57–59]. However, this handful of reports represented preliminary results, and
the authenticity of the transdifferentiated cells warranted further careful investigations. An early report suggested the in vivo transdifferentiation of pancreatic β-cell from other somatic cells with defined TFs [47]. Later, Fomina-Yadlin et al. reported that a compound *viz.* BRD7389 could potently transdifferentiate pancreatic α-cells to β-cells, as marked by similar phenotypic and gene expression signatures [57]. Katsuda et al. [59] revealed that the transdifferentiating activity of three small molecules, *viz.* A-83-01, Y-27632, and CHIR99021, could yield bipotent liver progenitor cells from mature hepatocytes. Of note, in vitro these liver progenitor cells can differentiate into biliary epithelial cells and active hepatocytes that can revive injured liver tissues in vivo. In another report, Wang et al. showed that a cocktail of defined chemicals, *viz.* Bay-K-8644, RG108, Bix01294, and SB431542, with tissue-specific mesenchymal feeders can facilitate transdifferentiation of human gastric epithelial cells to multipotent endodermal progenitor cells. These cells can further be systematically differentiated into hepatocytes, intestinal epithelial cells, and pancreatic endocrine cells [60].

### 3. Cellular Reprogramming in Disease Modeling

In 2006, the pioneering work of Yamanaka’s group demonstrated that forced expression of defined TFs *viz.* Oct4, Sox2, Klf4, c-Myc (OSKM; or Yamanaka factors) can instigate transcriptional reprogramming in murine somatic cells, converting them into induced pluripotent stem cells (iPSC) [61]. Replicating a similar strategy, human iPSCs were subsequently produced that revolutionized the field of regenerative medicine [62,63]. The human iPSCs were largely seen as a promising model for disease modeling and drug discovery, as these reflected the embryonic stem cells’ (ESCs) profile and had similar transcriptomic and chromatin signatures [63–65]. In a significant report, Cheng et al., working on murine fibroblasts and human urinary cells, for the first time successfully generated chemical-induced neural progenitor cells (ciNPCs) by treating cells with a three small molecules cocktail of valproic acid (VPA, i.e., propylpentanoic acid) —a HDAC inhibitor, CHIR99021—a GSK3 inhibitor—and Repsox—aTGFβ inhibitor [49]. They performed it under the physiological hypoxic (5% O₂) conditions, having no expression of exogenous TFs/genes [49]. Alternatively, taking cocktails of LiCl, NaB, and SB431542 or Li₂CO₃, TSA, and Tranilast with HDAC, GSK3, and TGFβ inhibitors, they further showed similar effects for ciNPC induction and the state of multipotency as these cells became differentiated into different neuronal cells in vitro and in vivo. The cellular reprogramming capabilities of both sets of TFs and chemical models reflected their immense clinical utility in disease modeling [63,65–67] (Figure 2).

Cellular reprogramming refers to a group of approaches that allow researchers to halt or reverse the development of adult cells. The validation of cellular reprogramming in human cells has paved the way for a slew of new stem cell biology, disease modeling, drug development, and regenerative medicine applications [19]. The presence of pluripotent stem cells in a population that gives rise to all cells is one of the most defining elements of early mammalian development [68]. Due to a shortage of primary cells from the human central nervous system (CNS) and peripheral nervous system, human-induced pluripotent stem cells (hiPSCs) can also be studied for neurogenerative disease [69]. However, researchers have been able to conduct studies on the recapitulation of physiological and pathological pathways in patient-derived lines. This has resulted in more realistic disease modeling platforms [70]. These are widely utilized in drug discovery and safety investigations, for instance in the development of AD drugs with the goal of identifying chemicals that can inhibit or lower amyloid-beta levels [71] (Tables 3 and 4).

Heart failure is another common illness that is linked to a high rate of morbidity and mortality. Coronary artery disease, genetic changes and mutations, viral infections, unfavorable immunological responses, and cardiac toxicity are the underlying causes [44]. This is due, in part, to roadblocks in translating research into treatment techniques. Drug repositioning using disease modeling systems based on hiPSCs could be a vital process that draws on prior toxicological and safety investigations to uncover new applications for
existing medications [72]. The components of the reprogramming cocktail, as well as the administration method, have undergone significant changes throughout time to improve efficiency and offer a safer product. The current problems that stymie the clinical utility of cellular reprogramming and its applications in biomedical research [65], drug discovery, and predictive safety pharmacology are the explicit topics covered in this review (Figure 3).

**3.1. Chemical/Small Molecule-Induced Cellular Reprogramming in Cardiomyocytes**

In 2015, a study reported full chemical-induced fibroblast to cardiomyocytes reprogramming for the first time. In this report, Fu et al. aimed to perform chemical induction of iPSCs (CiPSCs) of mice fibroblast using a chemical cocktail viz. CRFVPT that included CHIR99021, RepSox, Forskolin, VPA, Parnate, TTNPB [73] (Table 3). In the course of this, they observed the spontaneous formation of contractile patterns in the cells, and their clusters that were phenotypically similar to cardiomyocytes. Such a phenotype was evident 6-8 days post-treatment with the CRFVPT cocktail, which was quicker than an earlier published work that exhibited the emergence of the CiPSCs phenotype in 20 days [73]. They systematically performed the transdifferentiation using a two-stage strategy wherein the CRFVPT cocktail was utilized to instigate the induction in first stage and cardiomyocytes-supporting medium, with CHIR99021, PD0325901, LIF, and insulin supplements, was used in the second stage. With this two-stage strategy, the CRFV regime was found to potently stimulate cardiac transdifferentiation to CiCMs that appeared to progress through a progenitor stage [73].
Cao et al., using the small molecules, performed the successful reprogramming of fibroblast cells into functional cardiomyocytes [74]. Using a fibroblast cell line derived from the human foreskin, they transduced αMHC-GFP reporter in the cells and screened a library of 89 compounds, taking as reference a baseline cocktail. They found that a 7C recipe including CHIR99021, A83-01, AS8351, BIX01294, SC1, Y27632, and OAC2 was enough to efficiently instigate cardiac reprogramming. Additionally, in an extended screening, they found that two small molecules, *viz.* SU16F and JNJ10198409, that are known to be the inhibitors of PDGF signaling, can enrich the reprogramming population. On evaluating its in vivo performance, they found that these chemically treated cells can be transplanted into injured/infarcted hearts and can efficiently convert into cardiomyocyte-like cells in mouse models. In a recent report, Singh et al. recruited three small molecules, including sodium butyrate, ICG-001, and RA, along with GMT TFs and converted cardiomyocytes from primary rat heart fibroblasts [75]. The combinatorial approach was suggested to enhance the generation and induction of cardiomyocytes and offered an improvement of the cardiac regeneration practice for disease modeling (Table 3).

**Table 3.** Chemicals/small molecules-induced cellular reprogramming and their molecular activity/function(s) in neuronal and cardiac model systems.

| Chemicals/Small Molecules | Molecular Activity/Induced Mechanism(s) | Cellular Reprogramming Function(s) | References |
|--------------------------|----------------------------------------|----------------------------------|------------|
| RepSox (E-616452)        | TGF-βRI (ALK5) inhibitor               | CiNPC, CiN, CiCM                | [49,53,73] |
| TTNPB                    | RAR ligand                             | CiCM, CiN                        | [54,73]   |
| Forskolin                | Adenyl cyclase activator               | CiN, CiCM                        | [52,53,73]|
| CHIR99021                | GSK3 inhibitor                         | CiNPC, CiNSLc, CiNf, CiCM        | [52–54,73,74,76]|
| VPA                      | HDAC inhibitor                         | CiPSCa, CiNPCb, CiNC, CiCMe      | [49,53,54,73]|
| LiCl and Li2CO3          | GSK3 inhibitor                         | CiNPC                            | [49]     |
| SB431542                 | TGF-βRI inhibitor                      | CiPSC, CiNPC, CiN, hiEndoPC      | [49,54]  |
| NaB                      | HDAC inhibitor                         | CiNPC                            | [49]     |
| Tranilast                | Inhibit TGF-β1 secretion               | CiNPC                            | [49]     |
| TSA (Trichostatin A)     | HDAC inhibitor                         | CiNPC                            | [49]     |
| RG1018                   | DNA methyltransferase inhibitor        | CiNSLC                           | [50]     |
| A-83-01                  | TGF-βRI (ALK4/5/7) inhibitor           | CiNSLC, CiCM                     | [50,74]  |
| Hh-Ag 1.5                | Smoothened agonist                     | CiNSLC                           | [50]     |
| SMER28                   | Autophagy modulator                    | CiNSLC                           | [50]     |
| Retinoic acid            | RAR ligand                             | CiNSLC                           | [50]     |
| LDN193189                | BMP type I receptor (ALK2/3) inhibitor | CiNSLC                           | [50]     |
| GO6983                   | PKC inhibitor                          | CiN                              | [53]     |
| ISX9                     | neurogenesis inducer                   | CiN                              | [52]     |
| Dorsomorphin             | AMPK and BMP I receptor inhibitor      | CiN                              | [53]     |
| I-BET151                 | BET inhibitor                          | CiN                              | [52]     |
| SP600125                 | JNK inhibitor                          | CiN                              | [53]     |
| SAG                      | Smoothened agonist                     | CiN                              | [54]     |
| Y-27632                  | ROCK inhibitor                         | CiN, CiCM                        | [53,74]  |
| Purmorphamine            | Smoothened agonist                     | CiN                              | [54]     |
| DAPT                     | Gamma-secretase inhibitor              | CiN                              | [54]     |
Table 3. Cont.

| Chemicals/Small Molecules | Molecular Activity/Induced Mechanism(s) | Cellular Reprogramming Function(s) | References |
|---------------------------|----------------------------------------|----------------------------------|------------|
| SC1                       | ERK1 and RasGAP inhibitor              | CiCM                             | [74]       |
| Thiazovivin               | ROCK inhibitor                         | CiN                              | [54]       |
| OAC2                      | Epigenetic modulation                  | CiCM                             | [74]       |
| AS8351                    | Epigenetic modulator                   | CiCM                             | [74]       |
| SU16F                     | PDGFR-β inhibitor                       | CiCM                             | [74]       |
| JNJ10198409               | PDGFR-α and PDGFR-β inhibitor           | CiCM                             | [74]       |
| Bix01294                  | Histone methyl transferase inhibitor    | CiCM                             | [74]       |

CiN: chemical-induced neuron; CiNPC: chemical-induced neuroprogenitor cell; CiCM: chemical-induced cardiomyocyte; CiNSLC: chemical-induced neural stem cell-like cell.

3.2. Embryonic and Induced Pluripotent Stem Cells for Disease Modeling

Embryonic development starts with a single cell, the zygote, and progresses through the steps of establishing diverse cell lineages, eventually assimilating cells into the embryonic structure. It facilitates a high level of inter/intra-cellular communication and developmental cues that generate tissues and organ patterns to eventually shape the entire body [77]. Smith and colleagues firstly evaluated the osteogenic differentiation of mouse embryonic stem cells (ESCs) in vitro after their collection from mice (mESCs) [78]. Xu and colleagues later reported the isolation of human ESCs (hESCs) [79]. However, the conditions necessary to sustain pluripotency and self-renewal of mESCs and hESCs in vitro are quite different. Therefore, adult somatic cell-derived induced pluripotent stem cells (iPSCs) are rapidly being examined as a less controversial patient-specific alternative to hESCs. Importantly, iPSCs and ESCs have a high degree of similarity, providing new promise for the use of pluripotent stem cells for regenerative therapies with fewer ethical problems and potentially improved patient specificity [65] (Table 3). The development of innovative stem cell-based models to investigate the underlying processes of lineage differentiation and embryonic morphogenesis has been aided by the availability of embryo-derived stem cells that capture the lineage propensity [80].

Reprogramming the adult somatic cells into induced pluripotent stem cells (iPSCs) is another effective model that has a bright future as regenerative medicine. Therefore, disease models are critical for revealing the molecular basis of a variety of diseases, enabling the development of new treatments.
| Reprogramming Factors (TFs) | Species/Model/Cell Type | Obtained Cell Types | Efficiency | Results/Functional Outcome | References |
|----------------------------|------------------------|---------------------|------------|----------------------------|------------|
| Brn2, Myt1l, Zic1, Olig2, and Ascl1 | Mouse embryonic and postnatal fibroblast cells | iN (mostly GABAergic and glutamatergic neurons) | ~50% | Synaptic maturation, functional electrophysiology | [76] |
| Ascl1, Brn2 and Myt1l | Mouse embryonic fibroblast cells | iN (mostly excitatory neurons) | 19.50% | Synaptic maturation, functional electrophysiology | [76,81] |
| Forskolin, ISX9, CHIR99021 and SB431542 | Mouse fibroblast cells | iN | >90% | Functional electrophysiology | [52] |
| Ascl1, Brn2, Myt1l | Mouse hepatocytes | iN | >90% | Functional electrophysiology | [82] |
| Mash1, Nur71 and Lmx1a | Mouse and human cells/fibroblast cells | iN (mostly dopaminergic neurons) | High | - | [83] |
| Ascl1, Brn2 and Myt1l | Pericyte-derived cells of the adult human cerebral cortex | GABAergic neurons | ~50% | Obtained iN acquire the ability of action potential firing, synaptic targets for neurons | [84] |
| Sox2 and Mash1 | Human astrocytes | Functional neurons (mainly glutamatergic neurons) | >90% | Functional | [54] |
| ASCL1, NGN2, SOX2, NURR1 and PITX3 | Human fibroblast cells | iN (mostly dopaminergic neurons) | ~80% | Functional electrophysiology | [85] |
| NeuroD1, Ascl1, Brn2, and Myt1l | Human fibroblast cells | iN | ~60% | Functional neurons | [81] |
| Ascl1, Lmx1a, FoxA2, and FEV | Human fibroblast cells | serotonergic (5HT) neurons | ~25% | Showed spontaneous electrophysiological activity, Active synaptic transmission observed | [86] |
Table 4. Cont.

| Reprogramming Factors (TFs)                                    | Species/Model/Cell Type                                      | Obtained Cell Types            | Efficiency | Results/Functional Outcome                                      | References |
|----------------------------------------------------------------|-------------------------------------------------------------|--------------------------------|------------|-------------------------------------------------------------------|------------|
| **Cardiac**                                                    |                                                             |                                |            |                                                                   |            |
| GATA4, MEF2C, TBX5, HAND2                                      |                                                             | iCMs from MEFs                 | ~70–80%    | Spontaneous beating, Ca\(^{2+}\) transients                       | [87]       |
| GATA4, MYOD-MEF2C, TBX5, HAND2                                 |                                                             | iCMs from embryonic head fibroblasts | 10-20%    | Spontaneous beating, Ca\(^{2+}\) transients                       | [88]       |
| GATA4, MEF2C, TBX5, HAND2, NKX2.5, SB431542                    |                                                             | iCMs from MEFs                 | 17%        | Spontaneous beating, Ca\(^{2+}\) transients                       | [89]       |
| MEF2C, GATA4, TBX5                                             | Mouse                                                      | iCMs from CFs                  | ~10%       | Action potentials, spontaneous beating, Ca\(^{2+}\) transients     | [38]       |
| GATA4, MEF2C, TBX5, HAND2, miR-1, miR-133, A83-01, Y-27632     |                                                             | iCMs from MEFs                 | 60%        | Action potentials, spontaneous beating, Ca\(^{2+}\) transients     | [90]       |
| GATA4, MEF2C, TBX5, (HAND2), Bmi1 shRNA                       |                                                             | iCMs from CFs                  | 22%        | Spontaneous beating, Ca\(^{2+}\) transients                       | [91]       |
| GATA4, MEF2C, TBX5, SB431542, XAV939                           |                                                             | iCMs from CFs                  | ~30%       | Spontaneous beating, Ca\(^{2+}\) transients                       | [92]       |
| GATA4, MEF2C, TBX5, HAND2, DAPT                                |                                                             | iCMs from MEFs                 | ~38%       | Ca\(^{2+}\) transients, spontaneous beating                       | [93]       |
| GATA4, MEF2C, TBX5, MESP1, MYOCID                              | Human                                                      | iCMs from HCFs                 | 5.90%      | Ca\(^{2+}\) transients, action potentials                         | [94]       |
| GATA4, MEF2C, TBX5, ESRGG, MESP1, MYOCID, ZFPM2                |                                                             | iCMs from hESC-derived fibroblasts | 13%        | Ca\(^{2+}\) transients, action potentials                         | [95]       |
| GATA4, MEF2C, TBX5 (+ MESP1, MYOCID) with miR-133              |                                                             | iCMs from HCFs                 | 27.80%     | Ca\(^{2+}\) transients                                           | [96]       |
| GATA4, MEF2C, TBX5, (HAND2, MYOCID or miR-590)                 | Human, rat, porcine                                         | iCMs from adult HCFs           | ~40%       | No spontaneous beating in human iCMs                               | [97]       |
3.3. Cellular Reprogramming in Neuronal and Cardiac Disease Modeling

Neurons are the brain’s fundamental functional unit and are a diverse, dynamic, and important cell type in the study of cognitive function as well as the development of brain injury therapeutics [98]. Although the discovery of pluripotent transcription factors, including OSKM, were sufficient to efficiently transform mouse fibroblast cells into iPSCs [99], there are several drawbacks to existing iPSC technology, including the limited efficiency and a lengthy reprogramming process. Therefore, in molecular neurobiology, the direct reprogramming of somatic cells to distinct subtypes of induced neurons (iN) shows a lot of promise [100]. Certain transcription factor combinations are now known to directly create iN from a variety of cell types, which could be beneficial in the development of neurological illness models. This latest research is just the beginning of advancements that could allow us to use iN for disease modeling and medication in neurodegenerative diseases. The new generation of iN is crucial for understanding disease mechanisms and developing medications to treat neurodegenerative diseases (Table 4).

Human pluripotent stem cells (hPSCs) are also an extremely useful model system for studying the genetic basis of human cardiovascular disorders [67]. Unlike nonhuman animal models, human pluripotent stem cells (hPSCs) can be closely genetically matched to patients [101]. Hepatocytes, cardiomyocytes, and vascular endothelial and smooth muscle cells were all differentiated from hPSCs in large numbers and in a variety of cell types, which was crucial for determining the molecular underpinnings of the patient’s disease process [66]. Human embryonic stem cells (hESCs), first discovered in 1998, can be produced directly from human embryos. However, obtaining an hESC line often necessitates the destruction of an embryo that is unrelated to any live person [80]. As a result, induced pluripotent stem cells (iPSCs) are now the most important studies in which many types of human somatic cells have been effectively reprogrammed. One important goal related to patient-specific iPSCs will be to use or to create a cardiac-based model system that incorporates all the genetic loci involved in the pharmaceutical response [101] (Table 3). Clinically significant mutations can be extracted from the cells of patients suffering from a specific genetic disorder. One such study was performed considering the phenotype of iPSC-derived cardiomyocytes (iPSC-CMs) obtained from patients. These patients were more susceptible to catecholamine-induced tachyarrhythmia that was reduced by beta-blockade therapy [102]. These findings show that iPSCs may reliably recreate aberrant cellular phenotypes and behaviors in vitro, offering vital mechanistic insights into the disease process. It will be extremely valuable not only for disease modeling research (Table 1) but also for prospective clinical applications and high-content, large-scale drug screening methods (Tables 3 and 4).

3.4. Present Status, Developments, and Emerging Reprogramming Trends

Pluripotent stem cells (PSCs), which include embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), have a limitless ability to self-renew and proliferate. This feature allows them to generate a therapeutically relevant number of cells for regenerative therapy [24]. This would help the researchers to better understand the mechanisms driving a variety of human genetic, malignant, and nonmalignant disorders. Genome editing techniques have also been utilized to fix disease-specific iPSC mutations, resulting in gene-corrected iPSCs that can be employed for autologous cell-based treatment [103]. The number and kind of cells, their efficiency, footprint, and long-term translational goal influences all its reprogramming approaches. However, fibroblasts and peripheral blood mononuclear cells remain the gold standard, despite the usage of diverse cell types. When compared to iPSCs produced from other parental tissues, blood cells were less likely to develop aberrant DNA methylation, and these cells exhibited stronger hematopoietic differentiation ability [104,105]. Therefore, the generation of patient-specific iPSCs provides a safer alternative for clinical applications.

Transgenic animal models have traditionally been used to investigate disease pathogenesis but due to inherent variations across species, many of these models do not com-
pletely recreate illness characteristics [106]. As a result, most research has depended on the investigation of disease pathology using peripheral blood cells, which have a short lifespan in culture [104]. Genetic alterations, which are key tools for studying candidate gene function, are also hampered by the lack of a strategy to maintain and amplify the primary cells. The introduction of iPSC technology has revolutionized how we investigate reprogramming models and their derivatives for illuminating pathogenic events during disease start and progression. It would otherwise go undetected in primary cells [107]. Furthermore, in neuronal disorders, essential steps in generating and converting stem cell therapies from the bench to patients include identification of the proper stem cell type and understanding the mechanism of support [88]. There is substantial evidence that stem cell therapy can improve neurogenesis in patients with neurological diseases [108]. Cell-based chemical screening and animal testing have been used to develop a huge number of medications currently on the market [109]. However, numerous medications failed to reach the market due to unanticipated side effects in late-stage trials, primarily cardiotoxicity and hepatotoxicity. High-throughput screening assays against a library of hundreds of thousands of chemicals are possible because of a wide panel of disease-specific iPSCs and their derivatives [110]. This method may make it easier to design new treatments. Disease modeling is a crucial technique for elucidating the molecular basis of a variety of diseases and enabling the development of new targeted therapeutics. The concept of “disease in a dish” using ESCs/iPSCs has opened up new avenues for the experimentally derived understanding of disease mechanisms, paving the way for new targeted therapy alternatives [111]. Despite advancements in iPSC technology, the absence of efficient induction techniques continues to limit the creation of these cells [24]. Cost/resource needs, as well as the tendency of iPSCs to return to the genetic makeup of the original somatic cell type over time, are all ongoing concerns [112]. The present cellular reprogramming methods highlight the need for better stem cell production procedures. As a result, one of the ways that researchers developed was DeepNEU, a revolutionary unsupervised deep-machine learning framework for simulating iPSCs and enabling effective cellular reprogramming [113]. It was confirmed by creating computer simulations of three iPSC models that had previously been produced experimentally and published in peer-reviewed journals. The use of this computer technology to generate disease-specific artificially induced pluripotent stem cells (aiPSCs) has the potential to improve: (1) disease modeling; (2) rapid prototyping of wet-lab experiments; (3) grant application writing; and (4) specific biomarker identification, all at a low cost. This potential new technique is still being developed and validated, with the present focus on modeling rare genetic illnesses [65,113]. This shows that in the near future transdifferentiation and reprogramming therapies are expected to be successfully put into clinical practice.

4. Therapeutic Applications of Transdifferentiation and Cellular Reprogramming

4.1. Disease Modeling and Testing Therapeutics

A disease model represents the abnormal state of cells that occur in a specific disease. Therefore, it allows researchers to investigate and understand the intricate mechanisms that lead to the onset and further progression of the disease. These models can further be explored for developing and testing therapeutics. Cellular reprogramming of stem cells to create disease-in-a-dish models has gained a lot of attention over the past few years. These disease models are capable of self-renewal and also differentiate into desired cellular types to capture the disease pathogenesis [114] (Figure 3).

It was the use of ESCs derived from affected embryos that gave insights into the early developmental events of Fragile X Syndrome (FXS), the most common genetic cause of autism. It was found for the first time that FMR1 silencing of the mutated gene in an X-linked dominant manner happens only after differentiation and not in the embryonic stage [115]. Using iPSCs, one of the earliest disease models developed was to study spinal muscular atrophy. The motor neurons produced by diseased iPSCs carried the histological markers of the disease and degenerated at a rate faster than the wildtype
control neurons [116]. A disease model for schizophrenia established using iPSCs derived from patients with a 4 bp deletion in the DISC1 locus has also been reported. This is one of the successful examples where the episomal vector approach was used for the generation of adult patient-derived iPSCs without the risk of insertional mutagenesis [117]. Along similar lines, disease models for many other neurological disorders have been developed to date, including Rett syndrome [118], Down syndrome [119], Parkinson’s disease [120], and Alzheimer’s disease [121]. This iPSC technology has also been used to model various cardiac diseases including long QT syndrome, Leopard syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, arrhythmogenic right ventricular cardiomyopathy/dysplasia, dilated cardiomyopathy, left ventricular non-compaction, hypertrophic cardiomyopathy, Andersen–Tawil syndrome, Timothy syndrome, Friedreich’s ataxia, Barth syndrome, fatty acid oxidation disorders, and Pompe diseases. All these models have been discussed in detail in another report [122].

Organ-on-chip technology is another area showing progression at an accelerated rate. A group of researchers has generated a blood–brain barrier chip by integrating iPSCs and organ-on-chip technologies. These chips can serve good as a disease model for CNS drug penetrability predictions [123]. Another example is of a four-organ-chip consisting of interconnected miniaturized human intestine, liver, brain, and kidney equivalents created using pre-differentiated iPSCs. Three out of four models (intestine, liver, and neuronal) were shown to maintain defined marker expression under specific conditions for over 14 days; however, the renal model could not succeed as expected [124]. Nonetheless, these efforts expedite new avenues for modeling microphysiological systems. These systems can effectively be used as autologous coculture crosstalk assays, understanding the disease mechanisms, and for further using the platform for drug testing.

Along with providing mechanistic insights, these disease models have also been successfully employed to screen therapeutics. Many drug candidates that appear to be effective and safe in preclinical cellular and animal models often fail when tested in human beings. This can be attributed to the non-reliability of the preclinical models in practice. These models fail to recapitulate human physiology to its best. The popular cellular models for testing drug candidates include Chinese hamster ovary (CHO) cells and human embryonic kidney (HEK) cells. However, these cells do not reflect some of the important characteristics of human cardiomyocytes and also lack the expression of ion channels other than hERG. This often leads to incorrect assessments of drug effects. For instance, the action of Alfuzosin is mediated through sodium channels rather than hERG and causes QT prolongation. So, it appears to be non-toxic when tested in hERG-overexpressing cell lines [125]; however, testing in iPSC-CMs, it was identified as toxic [126]. This example thus clearly demonstrates the importance of correct screening models. Next, Long QT syndromes (LTQS) are caused by mutations in KCNQ1 or KCNH2. These genes encode voltage-gated potassium channels. The disease model for this syndrome, generated from iPSC-derived cardiomyocytes, showed significantly longer action potentials in comparison to the control cells. The dominant-negative trafficking effect of KCNQ1 and the resulting reduction in rectifier current was also studied through this model. Testing of known tests for this syndrome was then followed by the identification of β-adrenergic receptor inhibitors, nifedipine, and pinacidil as novel therapeutic candidates [127,128]. iPSC-derived disease models can also be effectively used for high-throughput screening assays. A study reported the use of neural stem cells differentiated from FXS patient-derived iPSCs in a 1536-well plate format high-throughput screening. Out of 5000 tested compounds, the authors were able to identify six compounds that modestly increased FMR1 gene expression in the patient-derived cells. Though the results did not provide any clue on their clinical application the study still proves the principle in question [129]. Next, iPSC-CMs have been reported to be employed for the screening of 131 different drugs at 6 different concentrations for the cardiotoxicity test [130]. Another similar study evaluated 51 previously characterized compounds in iPSC-CMs to study their effects on cardiomyocyte contraction [131]. The US FDA has also used iPSC-CMs for the evaluation
of drug-induced arrhythmic risk [132]. Further, a liposomal formulation of doxorubicin was also tested in a similar model. Doxorubicin in this new formulation was unable to penetrate cardiomyocytes, thereby approving its entry into phase I clinical trials [133].

4.2. Regenerative Medicine

The concept of regenerative medicine involves the switching of stem cells or dedifferentiating somatic cells into stem cell-like multipotent cells. These cells can proliferate and then re-differentiate into the desired lineage to repopulate the damaged or degenerated tissue with functional cells. The reprogramming of the cells can be conducted in vitro, in vivo, or ex vivo to regain their regenerative properties. The use of a single transcription factor, such as FOXN1, has been shown to regenerate the thymus in aged mice. Though a lot of efforts are being made to explore and understand mammalian stem cell biology, the knowledge regarding the regenerative capacity of the mammalian system is still limited. However, it is known that the cellular environment, including the modulators present in the extracellular matrix, cytokines, and growth factors, plays a crucial role in this process [134] (Figure 3).

There are plenty of examples that demonstrate the immense potential of regenerative medicine. The first clinical trials using stem cell-derived products for treating neurological diseases in human were initiated by Geron in 2009. The system used hESCs-derived oligodendrocytes to remyelinate denuded axons in patients with thoracic level spinal injury. However, the study faced preclusion due to financial concerns [135]. Since then, a lot of reports have been published that explore the utility of ESCs or iPSCs. In a more recent study, intervertebral disc-derived iPSCs differentiated into neural precursor cells were transplanted into mice to investigate the effect on spinal injury. The precursor cells were observed to differentiate into early and matured neurons, significantly improving the hindlimb dysfunction in the injured mice [136]. Making use of cell therapy for Parkinson’s disease requires the establishment of methods to produce human iPSCs or hESCs-derived midbrain-type dopaminergic neurons. Sundberg et al. developed a method for the same that resulted in the restoration of motor function in treated rats [137]. On similar grounds, iPSCs generated from nonobese diabetic mouse embryonic fibroblasts and pancreas-derived epithelial cells were reprogrammed to differentiate into functional pancreatic β-cells. These cells were further seen to produce insulin when transplanted into diabetic mice, thereby normalizing hyperglycemic conditions and paving way for treating diabetes [138]. The potential utility and feasibility of ESC or iPS-derived cardiomyocyte transplantation therapy for myocardial regeneration have also been discussed in many reports. It has been shown that embryonic-stem-cell-derived cardiomyocytes, when transplanted into a guinea-pig model with an injured heart, protected it against arrhythmias. The grafted muscles were also able to contract synchronously with the host muscle, improving the mechanical function of the injured heart and reducing the risk of ventricular tachycardia [139]. Though many other successful reports have come to light, we are discussing only a few to emphasize the clinical applications of this approach.

An alternative to the natural regenerative potential of mammalian stem cells is to induce transdifferentiation in somatic cells. Differentiated cells, such as neurons derived from iPSCs, have been observed to represent an embryolike stage. The epigenetic changes that a cell undergoes as it ages or becomes diseased are therefore not reflected by the matured cells. This results in the importance of the transdifferentiation process, whereby the phenotype of one somatic cell type can be converted into another without an intermediate progenitor stage [73]. For instance, Ieda and his colleagues used a combination of Gata4, Mef2c, and Tbx5 developmental transcription factors to transdifferentiate postnatal cardiac or dermal fibroblasts into cardiomyocyte-like cells. The gene expression profile and function of the differentiated cells was also found to be similar to the adult cardiomyocytes [140]. Similar studies enhancing the in vivo efficiency of cardiac cell reprogramming [141] and the use of small molecules for the same have also been reported [74].
4.3. Tissue Engineering

In simple words, tissue engineering refers to the in vitro production of tissues or organs for clinical applications using stem cell-derived differentiated cells. This technology is already in use, mainly for skin replacement and cartilage repair [142]. iPSCs and ESCs serve as an excellent source to produce desired cell types using cellular reprogramming or transdifferentiation (Figure 3).

iPSC-derived multipotent neural crest stem cells (NCSCs) supported by scaffold fabrication have previously been used to engineer nerve conduits for regenerating the sciatic nerve [143]. The rolling advancements in studies related to biomaterials, scaffold fabrication, 2D- and 3D-bioprinting have further accelerated development in the field of tissue engineering. Following this are some more examples to support this statement. Trans-differentiated endothelial cells capable of angiogenesis have been successfully utilized for re-endothelialization in tissue-engineered vessels [144]. Next, progress was made by utilizing the smooth muscle cells to generate functional endothelial cells [145]. Attempts have also been made at reprogramming hepatocytes for regenerating livers in mice [146]. This method was improved in a parallel study, and it resulted in the generation of trans-differentiated hepatocytes capable of synthesizing and excreting bile acid [147]. These developments can pave the way for treating cholestatic diseases as well. A recent study has further evolved the field by showing the generation and self-organization of kidneylike structures using hPSCs-derived renal cells. These organoids also contained functional glomeruli [148].

4.4. Gene Editing

Gene editing, in combination with stem cell technology, has the potential to revolutionize the field of medicine, especially for the corrective therapy of monogenic diseases such as sickle cell anemia. In the most simplistic representation, it works by generating patient-specific iPSCs, correcting the genetic defect, ex vivo/in vivo differentiation of the modified cells, followed by the transplantation of the corrected cells/tissue into the patient. The discovery of gene-editing tools, such as zinc finger nucleases, TALENS, and CRISPR/Cas9 has relatively simplified the process of gene editing, making the dream come true (Figure 3).

One of the encouraging examples here is the replacement of CAG expansion with normal repeats in the huntingtin gene in iPSCs derived from fibroblast cells of Huntington patients. The correction was sustained by the differentiation of DARPP-32-positive neurons as well under both in vitro and in vivo conditions [149]. A similar approach has also been used for correcting mutations in iPSCs derived from patients suffering from A1AT deficiency [150], sickle cell anemia [151], tauopathy [152], spinal muscular atrophy [153], and β-thalassemia [154].

Along with correcting the diseased phenotype, this combination of technologies can also be used to create and study genotypic alterations rarely found in the population. Thus, gene editing can be used to introduce disease-causing mutations into iPSCs or human ESCs from healthy donors. A group of researchers has used TALENs to mutate 15 different genes known to cause different disorders, including dyslipidemia, insulin resistance, hypoglycemia, lipodystrophy, motor neuron death, and hepatitis C virus infection [155].

4.5. Personalized Medicine

With advancements in next-generation sequencing technologies and cost-cutting, personalized medicines will soon become a routine procedure. With an increase in our understanding of stem cell biology and the evolution of genome editing tools, it is anticipated that the global vision of being able to treat almost any disease will soon become a reality. The above sections discussed many examples where patient-derived iPSCs have already been reprogrammed and differentiated into varied cell types depending upon the experimental/clinical objective (Figure 3).
iPSCs offer an efficient system for testing the effect of drugs in patients harboring different disease-associated mutations. The expected response of cardiovascular drugs such as warfarin, clopidogrel, and statins has been shown to be affected by the genotype of the patient. Therefore, choosing the right drug at the right dose for the right patient at the right time is one of the most important goals of precision medicine. As a supporting example, iPSC-CMs generated from patients with LQTS or hypertrophic cardiomyopathy were found to be more vulnerable to the arrhythmogenic effects of cisapride [156]. In another study, two potential IKs blockers increased the toxicity in iPSC-CMs from LQTS2 patients when compared to the control cells [157]. In yet another study, a patient with LQTS and frequent ventricular arrhythmias was found to have mutations in KCNH2 and SCN5A. The iPSC-CMs derived from this patient led to the finding that disease phenotype here was due to defects in the sodium channels and not the potassium channels. The patient was therefore administered mexiletine alone, a sodium channel blocker. The patient’s arrhythmias were controlled without the need for a secondary sodium channel blocker, flecainide [158].

Not only this, as described above, it has now become possible to create patient-specific iPSCs-derived disease models to understand the intricate disease mechanisms. Additionally, it is now feasible to monitor the effectiveness of specific drugs or their side-effects for informed therapeutic decisions. iPSC-CMs from 13 individuals were used to investigate the cardiotoxicity of 21 FDA approved tyrosine kinase inhibitors (used for treating various types of cancer) and generate a cardiac safety index [159]. Patients with monogenic genetic disorders can also benefit from gene-editing technologies. Another potential personalized application is to model a platform and assess the individual’s risk from specific environmental hazards. In one study, iPSC-CMs have also been used as an in vitro model for coxsackievirus B3–induced myocarditis [160].

Considering the clinical potential of iPSCs-based studies in clinical trials, in Table 5 we comprehensively listed some of the promising studies (including disease modelling, drug screening, and therapy-based studies) already in clinical trials. More details related to the experimental design and expected outcomes of each of the listed study can be accessed via https://www.clinicaltrials.gov/ (accessed on 25 July 2021) using the associated NCT number.
Table 5. Examples of iPSCs-based studies in clinical trials (Row 1 to 20—Disease modelling; Row 21 to 23—Drug screening; Row 24 to 31—Therapy based studies). More details related to the experimental design and expected outcomes of each of the listed study can be accessed from [https://www.clinicaltrials.gov/](https://www.clinicaltrials.gov/) (accessed on 25 July 2021) using the associated NCT number.

| S. No. | NCT Number | Title | Disease Condition | Phase | Location of Study |
|--------|-------------|-------|-------------------|-------|------------------|
| 1      | NCT02564484 | iPSC Neurons From Adult Survivors of Childhood Cancer Who Have Persistent Vincristine-Induced Neuropathy | Leukemia | Unknown | St. Jude Children’s Research Hospital, Memphis, Tennessee, United States |
| 2      | NCT01860898 | A Phase I Study of iPS Cell Generation From Patients With COPD | Thoracic Diseases | Not Applicable | Mayo Clinic in Rochester, Rochester, Minnesota, United States |
| 3      | NCT02980302 | Development of the Tool “iPSC” for the Functional Study of Mutations Responsible for Mental Retardation | Intellectual Deficiency | Not Applicable | University Hospital Grenoble, La Tronche, France |
| 4      | NCT02193724 | Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma | Retinoblastoma | Unknown | St. Jude Children’s Research Hospital, Memphis, Tennessee, United States |
| 5      | NCT02162953 | Stem Cell Models of Best Disease and Other Retinal Degenerative Diseases | Retinal Disease | Unknown | Mayo Clinic, Rochester, Minnesota, United States |
| 6      | NCT03883750 | Induced Pluripotent Stem Cells for Niemann Pick Disease | Niemann–Pick Diseases | Unknown | Childrens Hospital and Institute of Child Health, Ferozepur Road, Lahore, Pakistan |
| 7      | NCT03867526 | Establishment of Human Cellular Disease Models for Wilson Disease | Wilson Disease | Unknown | Childrens Hospital and Institute of Child Health, Ferozepur Road, Lahore, Pakistan |
| 8      | NCT03754088 | In vitro Model of the Cystic Fibrosis Bronchial Epithelium Via iPS Technology | Cystic Fibrosis | Unknown | Hôpital Arnaud de Villeneuve—CHU de Montpellier, Montpellier, France |
| S. No. | NCT Number | Title                                                                 | Disease Condition                                                                 | Phase       | Location of Study                                      |
|-------|------------|----------------------------------------------------------------------|----------------------------------------------------------------------------------|-------------|-------------------------------------------------------|
| 9     | NCT01534624| Stem Cell Study of Genetics and Drug Addiction                        | Induced Pluripotent Stem Cells                                                   | Unknown     | National Institute on Drug Abuse, Baltimore, Maryland, United States |
| 10    | NCT01865981| Investigating Hereditary Cardiac Disease by Reprogramming Skin Cells to Heart Muscle | Eletrophysiology of iPS-derived Cardiomyocytes                                   | Unknown     | University of Dundee, Dundee, Angus, United Kingdom   |
| 11    | NCT03872713| Establishment of Human Cellular Disease Models for Morquio Disease    | Morquio Disease                                                                   | Unknown     | Childrens Hospital and Institute of Child Health, Ferozepur Road, Lahore, Pakistan |
| 12    | NCT01639391| Creation of a Bank of Fibroblast From Patients With Amyotrophic Lateral Sclerosis: Pilot Study | Amyotrophic Lateral Sclerosis                                                     | Not Applicable | Centre rÃ©cent maladies rares SLA, Paris, France   |
| 13    | NCT03898817| Pathology of Helicases and Premature Aging: Study by Derivation of hiPS | Age Problem                                                                       | Unknown     | University Hospital Montpellier, Montpellier, France |
| 14    | NCT01571425| Evaluating Cardiovascular Phenotypes Using Induced Pluripotent Stem Cells | Coronary Artery Disease                                                           | Unknown     | Scripps Translational Science Institute, La Jolla, California, United States |
| 15    | NCT02413450| Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias | Inherited Cardiac Arrhythmias | Long QT Syndrome (LQTS) | Brugada Syndrome (BrS) | Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) | Early Repolarization Syndrome (ERS) | Arrhythogenic Cardiomyopathy (AC, ARVD/C) | Hypertrophic Cardiomyopathy (HCM) | Dilated Cardiomyopathy (DCM) | Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy) | Normal Control Subjects | Unknown | Johns Hopkins Medical Institute, Baltimore, Maryland, United States |
| 16    | NCT03682458| Study of Neurodegenerative Diseases Induced Stem Cells in Patients and Healthy Family Controls. | Neurodegenerative Diseases                                                        | Unknown     | Stefano Gambardella, Pozzilli, Isernia, Italy         |
| S. No. | NCT Number | Title                                                                 | Disease Condition                                      | Phase          | Location of Study                                                                 |
|-------|------------|----------------------------------------------------------------------|--------------------------------------------------------|----------------|----------------------------------------------------------------------------------|
| 17    | NCT03635294| Multi-Omics and iPSCs to Improve Diagnosis of Rare Intellectual Disabilities | Rare Intellectual Disabilities                         | Not Applicable | CHU Angers, Angers, France | HCL Lyon, Bron, France | CHU de Bourgogne, Dijon, France | CHU Nantes, Nantes, France | CHU Poitiers, Poitiers, France | CHU Rennes, Rennes, France |
| 18    | NCT03181204| Modeling Bronchial Epithelium Modifications Associated With COPD Using iPSC | Pulmonary Disease, Chronic Obstructive | Smoking | Unknown                                                  | Centre Hospitalier Universitaire de Montpellier, Montpellier, France |
| 19    | NCT02772367| Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients | Breast Cancer                                           | Unknown        | Memorial Sloan-Kettering Cancer Center, New York, New York, United States |
| 20    | NCT00895271| Establishing Fibroblast-Derived Cell Lines From Skin Biopsies of Patients With Immunodeficiency or Immunodysregulation Disorders | Primary Immunodeficiency | DOCK8            | Unknown                                                  | National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States |
| 21    | NCT01943383| Pharmacogenomic Evaluation of Antihypertensive Responses in Induced Pluripotent Stem (iPS) Cells Study | Hypertension                                           | Unknown        | University of Florida, Gainesville, Florida, United States |
| 22    | NCT04744532| iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study           | Amyotrophic Lateral Sclerosis                         | Phase 1        | Kyoto University, Kyoto, Japan | Kitasato University, Sagamihara, Japan | Tokushima University, Tokushima, Japan | Tottori University, Yonago, Japan |
| 23    | NCT04097275| Induced Pluripotent Stem Cells for the Development of Novel Drug Therapies for Inborn Errors of Metabolism (iPSC-IEM) | Inborn Errors of Metabolism                          | Unknown        | Children Hospital and Institute of Child Health, Lahore, Pakistan |
| 24    | NCT03407040| Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapy | Gastrointestinal Cancers | Breast Cancer | Pancreatic Cancer | Melanoma | Lung Cancer | Unknown        | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
Table 5. Cont.

| S. No. | NCT Number | Title                                                                 | Disease Condition                                      | Phase            | Location of Study                                                                 |
|--------|------------|----------------------------------------------------------------------|--------------------------------------------------------|------------------|----------------------------------------------------------------------------------|
| 25     | NCT04945018 | A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study) | Heart Failure | Ischemic Heart Disease              | Phase 1 | Phase 2                  | St. Marianna University Hospital, Kawasaki, Japan | Nihon University Itabashi Hospital, Tokyo, Japan | The University of Tokyo Hospital, Tokyo, Japan | Tokyo Medical and Dental University Medical Hospital, Tokyo, Japan | The University of Tokyo Hospital, Tokyo, Japan | Tokyo Metropolitan Geriatric Medical Center, Tokyo, Japan |
| 26     | NCT03403699 | Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy | Diabetes Complications | Diabetic Retinopathy | Unknown |                                        | University of Alabama at Birmingham, Birmingham, Alabama, United States |
| 27     | NCT04696328 | Clinical Trial of Human (Allogeneic) iPS Cell-derived Cardiomyocytes Sheet for Ischemic Cardiomyopathy | Myocardial Ischemia |                                        | Phase 1 |                                        | Osaka University Hospital, Suita, Osaka, Japan |
| 28     | NCT04339764 | Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration | Age-Related Macular Degeneration |                                        | Phase 1 | Phase 2                  | National Institutes of Health Clinical Center, Bethesda, Maryland, United States |
| 29     | NCT04982081 | Treating Congestive HF With hiPSC-CMs Through Endocardial Injection | Cardiovascular Diseases | Congestive Heart Failure | Dilated Cardiomyopathy | Phase 1 |                                        | Help Therapeutics, Nanjing, Jiangsu, China |
| 30     | NCT03971812 | Organoids Derived From Induced-Pluripotent Stem Cells (iPS) From Patients With High Grade Astrocytoma | Glioma |                                        | Unknown |                                        | Assistance Publique HÃ´pitaux de Marseille, Marseille, France |
| 31     | NCT03763136 | Treating Heart Failure With hPSC-CMs | Heart Failure |                                        | Phase 1 | Phase 2                  | HelpThera, Nanjing, Jiangsu, China |
5. Conclusions

Cell transdifferentiation and induced pluripotent stem cells have opened countless avenues with advancements in technologies that make it possible to reprogram these to differentiate into desired cell types. This field was further revolutionized by the development of methods that allow the direct transdifferentiation of somatic cells into a different cell lineage without the intermediate pluripotent state. This review discussed the various possible applications of these methods. It will soon be possible to study and understand any disease or disorder frequently existing or rarely found in a population. A wide variety of disease models have been developed to date with an inclination towards neurological, cardiac, hepatic, and cancer models. These transdifferentiated and induced models are also being applied for testing drugs and their efficient delivery into cells. A combination of the strength of iPSCs or hESCs with genome editing tools is also helping the scientific community to regulate genetic defects. Moreover, this cell fate differentiation technology is yet another step up in realizing the dream of personalized medicine for humankind.

Author Contributions: Investigation, data curation, R.S.K., J.K.D., M.D., B.S., R.N.; writing—original draft preparation, R.S.K., J.K.D., M.D., B.S., R.N.; writing—review and editing, R.S.K., J.K.D., M.D., B.S., R.N.; funding acquisition, J.K.D. All authors have read and agreed to the published version of the manuscript.

Funding: The APC was funded by Indraprastha Institute of Information Technology, Delhi.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Graf, T. Historical Origins of Transdifferentiation and Reprogramming. Cell Stem Cell 2011, 9, 504–516. [CrossRef] [PubMed]
2. Slack, J.M.W. Metaplasia and transdifferentiation: From pure biology to the clinic. Nat. Rev. Mol. Cell Biol. 2007, 8, 369–378. [CrossRef] [PubMed]
3. Jopling, C.; Boue, S.; Belmonte, J.C.I. Dedifferentiation, transdifferentiation and reprogramming: Three routes to regeneration. Nat. Rev. Mol. Cell Biol. 2011, 12, 79–89. [CrossRef] [PubMed]
4. Roccio, M. Directed differentiation and direct reprogramming: Applying stem cell technologies to hearing research. Stem Cells 2021, 39, 375–388. [CrossRef] [PubMed]
5. Guo, J.; Wang, H.; Hu, X. Reprogramming and Transdifferentiation Shift the Landscape of Regenerative Medicine. DNA Cell Biol. 2013, 32, 565–572. [CrossRef] [PubMed]
6. Zhao, Z.; Xu, M.; Wu, M.; Tian, X.; Zhang, C.; Fu, X. Transdifferentiation of Fibroblasts by Defined Factors. Cell. Reprogramm. 2015, 17, 151–159. [CrossRef]
7. Davis, R.L.; Weintrab, H.; Lassar, A.B. Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell 1987, 51, 987–1000. [CrossRef]
8. Murry, C.E.; Kay, M.A.; Bartosek, T.; Hauschka, S.D.; Schwartz, S.M. Muscle differentiation during repair of myocardial necrosis in rats via gene transfer with MyoD. J. Clin. Investig. 1996, 98, 2209–2217. [CrossRef] [PubMed]
9. Mollinari, C.; Zhao, J.; Lupacchini, L.; Garaci, E.; Merlo, D.; Pei, G. Transdifferentiation: A new promise for neurodegenerative diseases. Cell Death Dis. 2018, 9, 830. [CrossRef]
10. Barrett, N.R. The lower esophagus lined by columnar epithelium. Surgery 1957, 41, 881–894.
11. Tsukamoto, H.; She, H.; Hazra, S.; Cheng, J.; Miyahara, T. Anti-adipogenic regulation underlies hepatic stellate cell transdifferentiation. J. Gastroenterol. Hepatol. 2006, 21 (Suppl. 3), S102–S105. [CrossRef]
12. Hay, E.D.; Zuk, A. Transformations between epithelium and mesenchyme: Normal, pathological, and experimentally induced. Am. J. Kidney Dis. 1995, 26, 678–690. [CrossRef]
13. Li, Y.; Huard, J. Differentiation of Muscle-Derived Cells into Myofibroblasts in Injured Skeletal Muscle. Am. J. Pathol. 2002, 161, 895–907. [CrossRef]
14. Zhang, R.; Han, P.; Yang, H.; Ouyang, K.; Lee, D.; Lin, Y.-F.; Ocorr, K.; Kang, G.; Chen, J.; Stainier, D.Y.R.; et al. In vivo cardiac reprogramming contributes to zebrafish heart regeneration. Nature 2013, 498, 497–501. [CrossRef]
15. He, J.; Lu, H.; Zou, Q.; Luo, L. Regeneration of Liver After Extreme Hepatocyte Loss Occurs Mainly via Biliary Transdifferentiation in Zebrafish. Gastroenterology 2014, 146, 789–800. [CrossRef] [PubMed]
16. Suetsumu-Maki, R.; Maki, N.; Nakamura, K.; Sumanas, S.; Zhu, J.; Del Rio-Tsonis, K.; Tsonis, P.A. Lens regeneration in axolotl: New evidence of developmental plasticity. BMC Biol. 2012, 10, 103. [CrossRef] [PubMed]
17. Wang, T.; Chai, R.; Kim, G.S.; Pham, N.; Jansson, L.; Nguyen, D.-H.; Kuo, B.; May, L.A.; Zuo, J.; Cunningham, L.; et al. Lgr5+ cells regenerate hair cells via proliferation and direct transdifferentiation in damaged neonatal mouse utricle. Nat. Commun. 2015, 6, 6613. [CrossRef] [PubMed]
18. Chambers, S.M.; Studer, L. Cell Fate Plug and Play: Direct Reprogramming and Induced Pluripotency. Cell 2011, 145, 827–830. [CrossRef]
19. Cherry, A.B.; Daley, G.Q. Reprogramming Cellular Identity for Regenerative Medicine. Cell 2012, 148, 1110–1122. [CrossRef]
20. Baranek, M.; Belter, A.; Naskręt-Barciszewska, M.Z.; Stobiecki, M.; Markiewicz, W.T.; Barciszewski, J. Effect of small molecules on cell reprogramming. Mol. BioSyst. 2016, 13, 277–283. [CrossRef]
21. Julian, L.M.; McDonald, A.C.; Stanford, W.L. Direct reprogramming with SOX factors: Masters of cell fate. Curr. Opin. Genet. Dev. 2017, 46, 24–26. [CrossRef] [PubMed]
22. Cheung, C.T.; Singh, R.; Kalra, R.S.; Kaul, S.C.; Wadhwa, R. Collaborator of ARF (CARF) Regulates Proliferative Fate of Human Cells by Dose-dependent Regulation of DNA Damage Signaling. J. Biol. Chem. 2014, 289, 18258–18269. [CrossRef]
23. De Lazzaro, I.; Kostarelos, K. Engineering Cell Fate for Tissue Regeneration by In Vivo Transdifferentiation. Stem Cell Rev. Rep. 2015, 12, 129–139. [CrossRef] [PubMed]
24. Suman, S.; Domingues, A.; Ratajczak, J.; Ratajczak, M.Z. Potential Clinical Applications of Stem Cells in Regenerative Medicine. Adv. Exp. Med. Biol. 2019, 1201, 1–22. [CrossRef] [PubMed]
25. Kalra, R.S.; Chaudhary, A.; Omar, A.; Cheung, C.T.; Garg, S.; Kaul, S.C.; Wadhwa, R. Stress-induced changes in CARF expression determine cell fate to death, survival, or malignant transformation. Cell Stress Chaperones 2020, 25, 481–494. [CrossRef]
26. Wadhwa, R.; Kalra, R.S.; Kaul, S.C. CARF is a multi-module regulator of cell proliferation and a molecular bridge between cellular senescence and carcinogenesis. Mech. Ageing Dev. 2017, 166, 64–68. [CrossRef] [PubMed]
27. Torper, O.; Pfiester, U.; Wolf, D.A.; Pereira, M.; Lau, S.; Jakobsson, B.; Björklund, A.; Greasham, S.; Parmar, M. Generation of induced neurons via direct conversion in vivo. Proc. Natl. Acad. Sci. USA 2013, 110, 7038–7043. [CrossRef]
28. Rouaux, C.; Arlotta, P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. Nat. Cell Biol. 2013, 15, 1164–1175. [CrossRef]
29. Su, Z.; Niu, W.; Zang, T.; Smith, D.K.; Bachoo, R.; Zhang, C.-L. In vivo reprogramming of astrocytes to neuroblasts in the adult brain. Nat. Cell Biol. 2015, 5, 780–794. [CrossRef] [PubMed]
30. Niu, W.; Zang, T.; Zou, Y.; Fang, S.; Smith, D.K.; Bachoo, R.; Zhang, C.-L. SOX2 Reprograms Resident Astrocytes into Neural Progenitors in the Adult Brain. Stem Cell Rev. 2015, 11, 249–257. [CrossRef] [PubMed]
31. Yiu, G.; He, Z. Glial inhibition of CNS axon regeneration. Nat. Rev. Neurosci. 2006, 7, 617–627. [CrossRef]
32. De La Rossa, A.; Bellone, C.; Golding, B.J.; Vitali, I.; Moss, J.; Toni, N.; Lüscher, C.; Jabaoud, D. In vivo reprogramming of circuit connectivity in postmitotic neocortical neurons. Nat. Neurosci. 2013, 16, 193–200. [CrossRef] [PubMed]
33. Rouaux, C.; Arlotta, P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. Nat. Cell Biol. 2013, 15, 214–221. [CrossRef] [PubMed]
34. Rouaux, C.; Arlotta, P. Direct lineage reprogramming of post-mitotic callosal neurons into corticofugal neurons in vivo. Nat. Cell Biol. 2013, 15, 214–221. [CrossRef] [PubMed]
35. Qin, H.; Zhao, A.-K.; Sun, M.-L.; Ma, K.; Fu, X.-B. Direct reprogramming of functional neurons from brain injury and in an Alzheimer’s Disease Model. Cell Stem Cell 2014, 14, 188–202. [CrossRef] [PubMed]
36. De La Rossa, A.; Bellone, C.; Golding, B.J.; Vitali, I.; Moss, J.; Toni, N.; Lüscher, C.; Jabaoud, D. In vivo reprogramming of circuit connectivity in postmitotic neocortical neurons. Nat. Neurosci. 2013, 16, 193–200. [CrossRef] [PubMed]
37. Song, S.; Ashok, A.; Williams, D.; Kaufman, M.; Duff, K.; Sproul, A. Efficient Derivation of Excitatory and Inhibitory Neurons from Human Pluripotent Stem Cells Expressing Stably Reprogramming Factors. Curr. Protoc. 2021, 1, e141. [CrossRef] [PubMed]
38. Qian, L.; Huang, Y.; Spencer, C.I.; Foley, A.; Vedantham, V.; Liu, L.; Conway, S.J.; Fu, J.; Srivastava, D. In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nat. Cell Biol. 2012, 485, 593–598. [CrossRef] [PubMed]
39. Inagawa, K.; Miyamoto, K.; Yamakawa, H.; Muraoka, N.; Sadahiro, T.; Umei, T.; Wada, R.; Katsumata, Y.; Kaneda, R.; Nakade, K.; et al. Induction of Cardiomyocyte-Like Cells in Infarct Hearts by Gene Transfer of Gata4, Mef2c, and Tbx5. Circ. Res. 2012, 111, 114–117. [CrossRef] [PubMed]
40. Song, K.; Nam, Y.-J.; Luo, X.; Qi, X.; Tan, W.; Huang, G.; Acharya, A.; Smith, C.L.; Tallquist, M.; Neilson, E.G.; et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nat. Cell Biol. 2012, 485, 599–604. [CrossRef] [PubMed]
41. Jayawardena, T.M.; Finch, E.A.; Zhang, L.; Zhang, H.; Hodgkinson, C.P.; Pratt, R.E.; Rosenberg, P.; Mirotou, M.; Dzau, V.J. MicroRNA Induced Cardiac Reprogramming In Vivo: Evidence for mature cardiac myocytes and improved cardiac function. Circ. Res. 2015, 110, 418–424. [CrossRef] [PubMed]
42. Jayawardena, T.M.; Egemenzarov, B.; Finch, E.A.; Zhang, L.; Payne, J.A.; Pandya, K.; Zhang, Z.; Rosenberg, P.; Mirotou, M.; Dzau, V.J. MicroRNA-Mediated In Vitro and In Vivo Direct Reprogramming of Cardiac Fibroblasts to Cardiomyocytes. Circ. Res. 2012, 110, 1465–1473. [CrossRef] [PubMed]
43. Hu, Y.-F.; Dawkins, J.F.; Cho, H.C.; Marbán, E.; Cingolani, E. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci. Transl. Med. 2014, 6, 245ra94. [CrossRef] [PubMed]
44. Kapoor, N.; Liang, W.; Marbán, E.; Cho, H.C. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat. Biotechnol. 2013, 31, 54–62. [CrossRef] [PubMed]
45. Mozaffari, D.; Benjamin, E.J.; Go, A.S.; Arnett, D.K.; Blaha, M.J.; Cushman, M.; de Ferranti, S.; Després, J.-P.; Fullerton, H.J.; Howard, V.J.; et al. Heart Disease and Stroke Statistics—2015 Update: A report from the American Heart Association. Circulation 2015, 131, e29–e322. [CrossRef] [PubMed]
45. Christoforou, N.; Chellappan, M.; Adler, A.F.; Kirkton, R.D.; Wu, T.; Addis, R.C.; Bursac, N.; Leong, K.W. Transcription Factors MYOCD, SRF, Mesp1 and SMARCD3 Enhance the Cardio-Inducing Effect of GATA4, TBX5, and MEF2C during Direct Cellular Reprogramming. *PLoS ONE* 2013, 8, e63577. [CrossRef]

46. Christoforou, N.; Chakraborty, S.; Kirkton, R.D.; Adler, A.F.; Addis, R.C.; Leong, K.W. Core Transcription Factors, MicroRNAs, and Small Molecules Drive Transdifferentiation of Human Fibroblasts Towards the Cardiac Cell Lineage. *Sci. Rep.* 2017, 7, 40285. [CrossRef] [PubMed]

47. Zhou, Q.; Brown, J.; Kanarek, A.; Rajagopal, J.; Melton, D.A. In vivo reprogramming of adult pancreatic exocrine cells to β-cells. *Nat. Cell Biol.* 2008, 10, 655–663. [CrossRef]

48. Mathison, M.; Singh, V.P.; Chiuchiolo, M.J.; Sanagasetti, D.; Yao, M.; Patel, V.B.; Yang, J.; Kaminsky, S.; Crystal, R.G.; Rosengart, T.K. In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration. *J. Thorac. Cardiovasc. Surg.* 2017, 153, 329–339.e3. [CrossRef]

49. Cheng, L.; Hu, W.; Qiu, B.; Zhao, J.; Yu, Y.; Guan, W.; Wang, M.; Yang, W.; Pei, G. Generation of neural progenitor cells by chemical cocktails and hypoxia. *Cell Res.* 2014, 24, 665–679. [CrossRef] [PubMed]

50. Zhang, M.; Lin, Y.-H.; Sun, Y.J.; Zhu, S.; Zheng, J.; Liu, K.; Cao, N.; Li, K.; Huang, Y.; Ding, S. Pharmacological Reprogramming of Fibroblasts into Neural Stem Cells by Signaling-Directed Transcriptional Activation. *Cell Stem Cell* 2016, 18, 653–667. [CrossRef] [PubMed]

51. Medina, L.V.C.; Pasantes-Morales, H.; Aguilera-Castrejon, A.; Picones, A.; Lara-Figueroa, C.O.; Luís, E.; Montesinos, J.J.; Cortés-Morales, V.A.; Ruiz, M.P.D.R.; Hernández-Estévez, E.; et al. Neuronal Transdifferentiation Potential of Human Mesenchymal Stem Cells from Neonatal and Adult cells as a Small Molecule Cocktail. *Stem Cells Int.* 2019, 2019, 7627148. [CrossRef]

52. Li, X.; Zuo, X.; Jing, J.; Ma, Y.; Wang, J.; Liu, D.; Zhu, J.; Du, X.; Xiong, L.; Du, Y.; et al. Small-Molecule-Driven Direct Reprogramming of Mouse Fibroblasts into Functional Neurons. *Cell Stem Cell* 2015, 17, 195–203. [CrossRef]

53. Hu, W.; Qiu, B.; Guan, W.; Wang, Q.; Wang, M.; Li, W.; Gao, L.; Shen, L.; Huang, Y.; Xie, G.; et al. Direct Conversion of Normal and Alzheimer’s Disease Human Fibroblasts into Neuronal Cells by Small Molecules. *Cell Stem Cell* 2015, 17, 204–212. [CrossRef]

54. Zhang, L.; Yin, J.; Yeh, H.; Ma, N.-X.; Lee, G.; Chen, X.A.; Wang, Y.; Lin, L.; Chen, L.; Jin, P.; et al. Small Molecules Efficiently Reprogram Human Astroglial Cells into Functional Neurons. *Cell Stem Cell* 2015, 17, 735–747. [CrossRef]

55. Gautam, S.; Biswas, S.; Singh, B.; Guo, Y.; Deng, P.; Deng, W. Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine. *Curr. Med. Chem.* 2021, 28, 1. [CrossRef]

56. Xu, G.; Wu, F.; Gu, X.; Zhang, J.; You, K.; Chen, Y.; Getachew, A.; Zhuang, Y.; Zhong, X.; Lin, Z.; et al. Direct Conversion of Human Urine Cells to Neurons by Small Molecules. *Sci. Rep.* 2019, 9, 16707. [CrossRef] [PubMed]

57. Fomina-Yadlin, D.; Kubicek, S.; Walpita, D.; Dančík, V.; Hecksher-Sørensen, J.; Bittker, J.A.; Sharifnia, T.; Shamji, A.; Clemons, P.A.; Wagner, B.K.; et al. Small-molecule inducers of insulin expression in pancreatic -cells. *Proc. Natl. Acad. Sci. USA* 2010, 107, 15099–15104. [CrossRef] [PubMed]

58. Kostubenauer, S.; Zech, N.H.; Juch, H.; Vanderzwalmen, P.; Schoonjans, L.; Dohr, G. Embryonic Stem Cells: Similarities and Differences Between Human and Murine Embryonic Cells. *Am. J. Reprod. Immunol.* 2006, 55, 169–180. [CrossRef]

59. Katsuda, T.; Kawamata, M.; Hagiwara, K.; Takahashi, R.-U.; Yamamoto, Y.; Camargo, F.D.; Ochiya, T. Conversion of Terminally Committed Hematopoietic Cells to Culturable Bipotent Progenitor Cells with Regenerative Capacity. *Cell Stem Cell* 2017, 20, 41–55. [CrossRef] [PubMed]

60. Wang, Y.; Qin, J.; Wang, S.; Zhang, W.; Duan, J.; Zhang, J.; Wang, X.; Yan, F.; Chang, M.; Liu, X.; et al. Conversion of Human Gastric Epithelial Cells to Multipotent Endodermal Progenitors using Defined Small Molecules. *Cell Stem Cell* 2016, 19, 449–461. [CrossRef] [PubMed]

61. Takahashi, K.; Yamanaka, S. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors. *Cell* 2006, 126, 663–676. [CrossRef] [PubMed]

62. Takahashi, K.; Tanabe, K.; Ohnuki, M.; Narita, M.; Ichisaka, T.; Tomoda, K.; Yamanaka, S. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. *Cell* 2007, 131, 861–872. [CrossRef] [PubMed]

63. Smith, A.S.; Macadangdang, J.; Leung, W.; Lafleamme, M.; Kim, D.-H. Human iPSC-derived cardiomyocytes and tissue engineering strategies for disease modeling and screening. *Biotechnol. Adv.* 2017, 35, 77–94. [CrossRef] [PubMed]

64. Zhang, R.; Zhang, L.-H.; Xie, X. iPSCs and small molecules: A reciprocal effort towards better approaches for drug discovery. *Acta Pharmacol. Sin.* 2013, 34, 765–776. [CrossRef] [PubMed]

65. Doss, M.X.; Sachinidis, A. Current Challenges of iPSC-Based Disease Modeling and Therapeutic Implications. *Cells* 2019, 8, 403. [CrossRef]

66. Bai, X. Stem Cell-Based Disease Modeling and Cell Therapy. *Cells* 2020, 9, 2193. [CrossRef]

67. Saito-Diaz, K.; Zeltner, N. Induced pluripotent stem cells for disease modeling, cell therapy and drug discovery in genetic autonomic disorders: A review. *Clin. Auton. Res.* 2019, 29, 367–384. [CrossRef]

68. Baillie-Benson, P.; Moris, N.; Arias, A.M. Pluripotent stem cell models of early mammalian development. *Curr. Opin. Cell Biol.* 2020, 66, 89–96. [CrossRef]

69. Ford, E.; Pearlman, J.; Ruan, T.; Manion, J.; Waller, M.; Neely, G.G.; Caron, L. Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges. *Cells* 2020, 9, 2517. [CrossRef]

70. Kim, S.-Y.; Kim, Y.-R.; Park, W.-J.; Kim, H.S.; Jung, S.-C.; Woo, S.-Y.; Jo, I.; Ryu, K.-H.; Park, J.-W. Characterisation of insulin-producing cells differentiated from tonsi derived mesenchymal stem cells. *Differentiation* 2015, 90, 27–39. [CrossRef]
71. González, J.F.; Alcántara, A.R.; Doadrio, A.L.; Sánchez-Montero, J.M. Developments with multi-target drugs for Alzheimer’s disease: An overview of the current discovery approaches. *Expert Opin. Drug Discov.* 2019, 14, 879–891. [CrossRef] [PubMed]

72. Finheiro, E.A.; Fetterman, K.A.; Burridge, P.W. hiPSCs in cardio-oncology: Deciphering the genomics. *Cardiovasc. Res.* 2019, 115, 935–948. [CrossRef] [PubMed]

73. Xu, Y.; Huang, C.; Xu, X.; Gu, H.; Ye, Y.; Jiang, C.; Qiu, Z.; Xie, X. Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails. *Cell Res.* 2015, 25, 1013–24. [CrossRef] [PubMed]

74. Cao, N.; Huang, Y.; Zheng, J.; Spencer, C.I.; Zhang, Y.; Fu, J.-D.; Nie, B.; Xie, M.; Zhang, M.; Wang, H.; et al. Conversion of human fibroblasts into functional cardiomyocytes by small molecules. *Science 2016*, 352, 1216–1220. [CrossRef] [PubMed]

75. Singh, V.P.; Pinnamaneni, J.P.; Pugazhenthi, A.; Sanagasetti, D.; Mathison, M.; Wang, K.; Yang, J.; Rosengart, T.K. Enhanced Generation of Induced Cardiomyocytes Using a Small-Molecule Cocktail to Overcome Barriers to Cardiac Cellular Reprogramming. *J. Am. Heart Assoc.* 2020, 9, e015686. [CrossRef] [PubMed]

76. Vierbuchen, T.; Ostermeier, A.; Pang, Z.; Kokubu, Y.; Südhof, T.C.; Wernig, M. Direct conversion of fibroblasts to functional neurons by defined factors. *Nat. Cell Biol.* 2010, 16, 1035–1041. [CrossRef] [PubMed]

77. Rossant, J.; Tam, P.P. Opportunities and challenges with stem cell-based embryo models. *Stem Cell Rep.* 2021, 16, 1031–1038. [CrossRef] [PubMed]

78. Smith, L.A.; Liu, X.; Hu, J.; Wang, P.; Ma, P.X. Enhancing Osteogenic Differentiation of Mouse Embryonic Stem Cells by Nanofibers. *Tissue Eng. Part A* 2009, 15, 1855–1864. [CrossRef] [PubMed]

79. Xu, N.; Papagiannakopoulos, T.; Pan, G.; Thomson, J.A.; Kosik, K.S. MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Stem Cell Models. *Cell Stem Cell* 2009, 4, 137, 647–658. [CrossRef] [PubMed]

80. Kingham, E.; Orefio, R.O. Embryonic and Induced Pluripotent Stem Cells: Understanding, Creating, and Exploiting the Nano-Niche for Regenerative Medicine. *ACS Nano* 2013, 7, 1867–1881. [CrossRef] [PubMed]

81. Pang, Z.; Yang, N.; Vierbuchen, T.; Ostermeier, A.; Fuentes, D.; Yang, T.Q.; Citri, A.; Sebastian, V.; Marro, S.; Südhof, T.C.; et al. Induction of human neuronal cells by defined transcription factors. *Nat. Cell Biol.* 2011, 476, 220–223. [CrossRef] [PubMed]

82. Marro, S.; Pang, Z.; Yang, N.; Tsai, M.-C.; Qu, K.; Chang, H.Y.; Südhof, T.C.; Wernig, M. Direct Lineage Conversion of Terminally Differentiated Hepatocytes to Functional Neurons. *Cell Stem Cell* 2011, 9, 374–382. [CrossRef] [PubMed]

83. Caliazzo, M.; Dell’Anno, M.T.; Vierbuchen, S.; Lavarello, D.; Tavera, S.; Leo, D.; Sotnikova, T.D.; Menegon, A.; Roncaglia, P. Colciago, G.; et al. Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. *Nat. Cell Biol.* 2011, 476, 224–227. [CrossRef] [PubMed]

84. Karow, M.; Sánchez, R.; Schichor, C.; Masserottig, D.; Ortega, F.; Heinrich, C.; Gascon, S.; Khan, M.A.; Lie, D.C.; Dellavalle, A.; et al. Reprogramming of Pericyte-Derived Cells of the Adult Human Brain into Induced Neuronal Cells. *Cell Stem Cell 2012*, 11, 471–476. [CrossRef] [PubMed]

85. Liu, X.; Li, F.; Stubblefield, E.A.; Blanchard, B.; Richards, T.L.; Larson, G.A.; He, Y.; Huang, Q.; Pan, A.C.; Zhang, D.; et al. Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells. *Cell Res.* 2011, 22, 321–332. [CrossRef] [PubMed]

86. Xu, Z.; Jiang, H.; Zhong, P.; Yan, Z.; Chen, S.; Feng, J. Direct conversion of human fibroblasts to induced serotonergic neurons. *Mol. Psychiatry* 2015, 21, 62–70. [CrossRef] [PubMed]

87. Zhang, Z.; Zhang, W.; Nam, Y.-J. Stoichiometric optimization of Gata4, Hand2, Mef2c, and Tbx5 expression for contractile cardiomyocyte reprogramming. *Sci. Rep.* 2019, 9, 14970. [CrossRef] [PubMed]

88. Hirai, H.; Katoku-Kikyo, N.; Keirstead, S.A.; Kikyo, N. Accelerated direct reprogramming of fibroblasts into cardiomyocyte-like cells with the MyoD transactivation domain. *Cardiovasc. Res.* 2013, 100, 105–113. [CrossRef] [PubMed]

89. Ikkovits, J.L.; Addis, R.C.; Epstein, J.A.; Gehrardt, J.D. Inhibition of TGFβ Signaling Increases Direct Conversion of Fibroblasts to Induced Cardiomyocytes. *PLoS ONE 2014*, 9, e89678. [CrossRef] [PubMed]

90. Zhao, Y.; Londono, P.; Cao, Y.; Sharpe, E.J.; Proenza, C.; O’Rourke, R.; Jones, K.L.; Jeong, M.Y.; Walker, L.; Buttrick, P.M.; et al. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. *Nat. Commun.* 2015, 6, 8243. [CrossRef] [PubMed]

91. Zhou, Y.; Wang, L.; Vaseghi, H.R.; Liu, Z.; Lu, R.; Alimohamadi, S.; Yin, C.; Fu, J.; Wang, G.G.; Liu, J.; et al. Bmi1 Is a Key Epigenetic Barrier to Direct Cardiac Reprogramming. *Cell Stem Cell 2016*, 18, 382–395. [CrossRef] [PubMed]

92. Mohamed, T.M.A.; Stone, N.R.; Berry, E.C.; Radzinsky, E.; Huang, Y.; Pratt, K.; Ang, Y.-S.; Yu, P.; Wang, H.; Tang, S.; et al. Chemical Enhancement of In Vitro and In Vivo Direct Cardiac Reprogramming. *Circulation 2017*, 135, 978–995. [CrossRef] [PubMed]

93. Haratizadeh, S.; Bojnordi, M.N.; Darabi, S.; Karimi, N.; Naghkhani, M.; Hamidabadi, H.G.; Seifi, M. Condition medium of cerebrospinal fluid and retinoic acid induces the transdifferentiation of human dental pulp stem cells into neuroglia and neural like cells. *Anat. Cell Biol.* 2017, 50, 107–114. [CrossRef] [PubMed]

94. Wada, R.; Muraoka, N.; Inagawa, K.; Yamakawa, H.; Miyamoto, K.; Sadahiro, T.; Umei, T.; Kaneda, R.; Suzuki, T.; Kamiya, K.; et al. Induction of human cardiomyocyte-like cells from fibroblasts by defined factors. *Proc. Natl. Acad. Sci. USA* 2013, 110, 12667–12672. [CrossRef] [PubMed]

95. Fu, J.; Stone, N.R.; Liu, L.; Spencer, C.I.; Qian, L.; Hayashi, Y.; Olguin, P.D.; Ding, S.; Bruneau, B.G.; Srivastava, D. Direct Reprogramming of Human Fibroblasts toward a Cardiomyocyte-like State. *Stem Cell Rep.* 2013, 1, 235–247. [CrossRef] [PubMed]

96. Muraoka, N.; Yamakawa, H.; Miyamoto, K.; Sadahiro, T.; Umei, T.; Isomi, M.; Nakashima, H.; Akiyama, M.; Wada, R.; Inagawa, K.; et al. MiR-133 promotes cardiac reprogramming by directly repressing Snai1 and silencing fibronectin signatures. *EMBO J.* 2014, 33, 1565–1581. [CrossRef] [PubMed]
97. Singh, V.P.; Mathison, M.; Patel, V.; Sanagastia, D.; Gibson, B.W.; Yang, J.; Rosengart, T.K. MiR-590 Promotes Transdifferentiation of Porcine and Human Fibroblasts Toward a Cardiomyocyte-Like Fate by Directly Repressing Specificity Protein 1. J. Am. Heart Assoc. 2016, 5, e003922. [CrossRef] [PubMed]

98. Sivandzade, F.; Cucullo, L. Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. Int. J. Mol. Sci. 2021, 22, 2153. [CrossRef]

99. Takahashi, K.; Yamanaka, S. A decade of transcription factor-mediated reprogramming to pluripotency. Nat. Rev. Mol. Cell Biol. 2016, 17, 183–193. [CrossRef]

100. Kim, J.; Ambasudhan, R.; Ding, S. Direct lineage reprogramming to neural cells. Curr. Opin. Neurobiol. 2012, 22, 778–784. [CrossRef]

101. Musunuru, K.; Sheikh, F.; Gupta, R.M.; Houser, S.R.; Maher, K.O.; Milan, D.J.; Terzic, A.; Wu, J.C. Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling and Precision Medicine: A Scientific Statement From the American Heart Association. Circ. Genom. Precis. Med. 2018, 11, e000043. [CrossRef] [PubMed]

102. Preininger, M.; Jha, R.; Maxwell, J.T.; Wu, Q.; Singh, M.; Wang, B.; Dalal, A.; Meeachin, Z.T.; Rossoll, W.; Hales, C.M.; et al. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses. Dis. Model. Mech. 2016, 9, 927–939. [CrossRef] [PubMed]

103. Ben Jehuda, R.; Shemer, Y.; Binah, O. Genome Editing in Induced Pluripotent Stem Cells using CRISPR/Cas9. Stem Cell Rev. Rep. 2018, 14, 323–336. [CrossRef] [PubMed]

104. Wattanapanich, M. Recent Updates on Induced Pluripotent Stem Cells in Hematological Disorders. Stem Cells Int. 2019, 2019, 5171032. [CrossRef]

105. Nishizawa, M.; Chonabayashi, K.; Nomura, M.; Tanaka, A.; Nakamura, M.; Inagaki, A.; Nishikawa, M.; Takei, I.; Oishi, A.; Tanabe, K.; et al. Epigenetic Variation between Human Induced Pluripotent Stem Cell Lines Is an Indicator of Differentiation Capacity. Cell Stem Cell 2016, 19, 341–354. [CrossRef] [PubMed]

106. Guerrero-Aspizua, S.; Carretero, M.; Conti, C.J.; Del Rio, M. The importance of immunity in the development of reliable animal models for psoriasis and atopic dermatitis. Immunol. Cell Biol. 2020, 98, 626–638. [CrossRef]

107. Brandão, K.O.; Tabel, V.A.; Atsma, D.E.; Mummery, C.; Davis, R.P. Human pluripotent stem cell models of cardiac disease: From mechanisms to therapies. Dis. Models Mech. 2017, 10, 1039–1059. [CrossRef]

108. Sharma, P.; Ando, D.; Daub, A.; Kaye, J.A.; Finkbeiner, S. High-Throughput Screening in Primary Neurons. Stem Cell Transl. Med. 2015, 4, 381–388. [CrossRef] [PubMed]

109. Lindvall, O.; Kokaia, Z.; Martinez-Serrano, A. Stem cell therapy for human neurodegenerative disorders—How to make it work. Nat. Med. 2004, 10, S42–S50. [CrossRef]

110. Hunsberger, J.G.; Rao, M.; Kurtzberg, J.; Bulte, J.W.M.; Atala, A.; LaFerla, F.M.; Greely, H.T.; Sawa, A.; Gandy, S.; Schneider, L.S.; et al. Accelerating stem cell trials for Alzheimer’s disease. Lancet Neurol. 2016, 15, 219–230. [CrossRef]

111. Mummery, C.; Davis, R.P.; Atsma, D.E.; Mummery, C.; Davis, R.P. Human pluripotent stem cell models of cardiac disease: From mechanisms to therapies. Dis. Models Mech. 2017, 10, 1039–1059. [CrossRef] [PubMed]

112. Sharma, P.; Ando, D.; Daub, A.; Kaye, J.A.; Finkbeiner, S. High-Throughput Screening in Primary Neurons. Methods Enzymol. 2012, 506, 331–360. [CrossRef] [PubMed]

113. Eiges, R.; Urbach, A.; Malcov, M.; Frumkin, T.; Schwartz, T.; Amit, A.; Yaron, Y.; Eden, A.; Yanuka, O.; Benvenisty, N.; et al. Developmental Study of Fragile X Syndrome Using Human Embryonic Stem Cells Derived from Preimplantation Genetically Diagnosed Embryos. Cell Stem Cell 2007, 1, 568–577. [CrossRef] [PubMed]

114. Ebert, A.D.; Yu, J.; Rose, F.F.; Mattis, V.B.; Lorson, C.L.; Thomson, J.A.; Svendsen, C.N. Induced pluripotent stem cells from a spinal muscular atrophy patient. Nat. Cell Biol. 2008, 457, 277–280. [CrossRef] [PubMed]

115. Benguigui, O.; Kokaia, Z.; Martinez-Serrano, A. Stem cell therapy for human neurodegenerative disorders—How to make it work. Orphanet J. Rare Dis. 2019, 14, 13. [CrossRef] [PubMed]

116. Sanchez-Danes, A.; Richaud-Patin, Y.; Carballo-Carbiaj, I.; Delgado, S.J.; Caig, C.; Mora, S.; Di Guglielmo, C.; Ezquerra, M.; Patel, B.; Giralt, A.; et al. Disease-specific phenotypes in dopamine neurons from human iPS-based models of genetic and sporadic Parkinson’s disease. EMBO Mol. Med. 2012, 4, 380–395. [CrossRef] [PubMed]

117. Yagi, T.; Ito, D.; Okada, Y.; Akamatsu, W.; Nihei, Y.; Yoshizaki, T.; Yamanaka, S.; Okano, H.; Suzuki, N. Modeling familial Alzheimer’s disease in patient iPS cells. Hum. Mol. Genet. 2011, 20, 4530–4539. [CrossRef] [PubMed]

118. Parrotta, E.L.; Lucchino, V.; Scaramuzzino, L.; Scalise, S.; Cuda, G. Modeling Cardiac Disease Mechanisms Using Induced Pluripotent Stem Cell-Derived Cardiomyocytes: Progress, Promises and Challenges. Int. J. Mol. Sci. 2020, 21, 4354. [CrossRef] [PubMed]
123. Jagadeesan, S.; Workman, M.J.; Herland, A.; Svendsen, C.N.; Vatine, G.D. Generation of a Human iPSC-Based Blood-Brain Barrier Chip. J. Vis. Exp. 2020, 157, e60925. [CrossRef]

124. Ramme, A.P.; Koenig, L.; Hasenberg, T.; Schwenk, C.; Magauer, C.; Faust, D.; Lorenz, A.K.; Krebs, A.-C.; Drewell, C.; Schirrmann, K.; et al. Autologous induced pluripotent stem cell-derived four-organ-chip. Future Sci. OA 2019, 5, FS0413. [CrossRef]

125. Lacerda, A.E.; Kuryshev, Y.A.; Chen, Y.; Renganathan, M.; Eng, H.; Danthi, S.J.; Kramer, J.W.; Yang, T.; Brown, A.M. Alfluzosin Delays Cardiac Repolarization by a Novel Mechanism. J. Pharmacol. Exp. Ther. 2007, 324, 427–433. [CrossRef]

126. Navarrete, E.G.; Liang, P.; Fan, L.; Sanchez-Freire, V.; Simmons, C.; Gong, T.; Sharma, A.; Burridge, P.W.; Patlolla, B.; Lee, A.S.; et al. Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays. Circulation 2013, 128, S3–S13. [CrossRef] [PubMed]

127. Moretti, A.; Bellini, M.; Wellin, A.; Jung, C.B.; Lam, J.T.; Bott-Flügel, L.; Dorn, T.; Goedel, A.; Höhnke, C.; Hofmann, F.; et al. Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome. N. Engl. J. Med. 2010, 363, 1397–1409. [CrossRef] [PubMed]

128. Itzhaki, I.; Maizels, L.; Huber, I.; Zwi-Dantsis, L.; Caspi, O.; Winterstern, A.; Feldman, O.; Arbég, A.; Hamermon, H.; et al. Modelling the long QT syndrome with human induced pluripotent stem cells. Nat. Cell Biol. 2011, 471, 225–229. [CrossRef] [PubMed]

129. Pointon, A.; Harmer, A.R.; Dale, I.L.; Abi-Gerges, N.; Bowes, J.; Pollard, C.; Garside, H. Assessment of Cardiomyocyte Contraction in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Toxicol. Sci. 2015, 144, 227–237. [CrossRef] [PubMed]

130. Blinova, K.; Stohlman, J.; Vicente, J.; Chan, D.; Johannesen, L.; Hortigón-Vinagre, M.P.; Zamora, V.; Smith, G.; Crumb, W.J.; Pang, L.; et al. Comprehensive Translational Assessment of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Evaluating Drug-Induced Arrhythmias. Toxicol. Sci. 2017, 155, 234–247. [CrossRef]

131. Reynolds, J.G.; Geretti, E.; Hendriks, B.S.; Lee, H.; Leonard, S.C.; Klinz, S.G.; Noble, C.O.; Lücker, P.B.; Zandstra, P.W.; Drummond, D.C.; et al. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicol. Appl. Pharmacol. 2012, 262, 1–10. [CrossRef] [PubMed]

132. Colwell, A.S.; Longaker, M.T.; Lorenz, H.P. Mammalian Fetal Organ Regeneration. Blue Biotechnol. 2005, 93, 83–100. [CrossRef]

133. Frantz, S. Embryonic stem cell pioneer Geron exits field, cuts losses. Nat. Biotechnol. 2012, 30, 12–13. [CrossRef]

134. Jeon, K.; Lim, H.; Kim, H.-T.; You, Y.; Yoon, D.H.; Song, K.Y.; Cheong, E.; Ha, Y.; Hwang, D.-Y. Human-induced pluripotent stem cells generated from intervertebral disc cells improve neurologic functions in spinal cord injury. Stem Cell Res. Ther. 2015, 6, 125. [CrossRef]

135. Mathison, M.; Gersch, R.P.; Nasser, A.; Lilo, S.; Korman, M.; Fourman, M.; Hackett, N.; Shroyer, K.; Yang, T.; Ma, Y.; et al. Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays. Circulation 2013, 128, S3–S13. [CrossRef] [PubMed]

136. Mathison, M.; Fourman, M.; Lilo, S.; Korman, M.; Hackett, N.; Shroyer, K.; Yang, T.; Ma, Y.; et al. Improved Cell Therapy Protocols for Parkinson’s Disease Based on Differentiation Efficiency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons. Stem Cells 2013, 31, 1548–1562. [CrossRef] [PubMed]

137. Ieda, M.; Fu, J.; Olguín, P.D.; Vedantham, V.; Hayashi, Y.; Bruneau, B.; Srivastava, D. Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors. Cell 2010, 142, 375–386. [CrossRef] [PubMed]

138. Mathison, M.; Gersch, R.P.; Rasser, A.; Lilo, S.; Korman, M.; Fourman, M.; Hackett, N.; Shroyer, K.; Yang, T.; Ma, Y.; et al. Improved Cell Therapy Protocols for Parkinson’s Disease Based on Differentiation Efficiency and Safety of hESC-, hiPSC-, and Non-Human Primate iPSC-Derived Dopaminergic Neurons. Stem Cells 2013, 31, 1548–1562. [CrossRef] [PubMed]

139. Berthiaume, F.; Maguire, T.J.; Yarmush, M.L. Tissue Engineering and Regenerative Medicine: History, Progress, and Challenges. Annu. Rev. Chem. Biomol. Eng. 2011, 2, 403–430. [CrossRef]

140. Wang, A.; Tang, Z.; Park, I.-H.; Zhu, Y.; Patel, S.; Daley, G.Q.; Li, S. Induced pluripotent stem cells for neural tissue engineering. Biomaterials 2011, 32, 5023–5032. [CrossRef]

141. Margariti, A.; Winkler, B.; Karamariti, E.; Zampetaki, A.; Tsai, T.-N.; Baban, D.; Ragoussis, J.; Huang, Y.; Han, J.-D.J.; Zeng, L.; et al. Direct reprogramming of fibroblasts into endothelial cells capable of angiogenesis and reendothelialization in tissue-engineered vessels. Proc. Natl. Acad. Sci. USA 2012, 109, 13793–13798. [CrossRef] [PubMed]

142. Hong, X.; Margariti, A.; Le Bras, A.; Jacquet, L.; Kong, W.; Hu, Y.; Xu, Q. Transdifferentiated Human Vascular Smooth Muscle Cells are a New Potential Cell Source for Endothelial Regeneration. Sci. Rep. 2017, 7, 5590. [CrossRef] [PubMed]

143. Moretti, A.; Bellini, M.; Wellin, A.; Jung, C.B.; Lam, J.T.; Bott-Flügel, L.; Dorn, T.; Goedel, A.; Höhnke, C.; Hofmann, F.; et al. Patient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome. N. Engl. J. Med. 2010, 363, 1397–1409. [CrossRef] [PubMed]
147. Limaye, P.B.; Bowen, W.C.; Orr, A.; Apte, U.M.; Michalopoulos, G.K. Expression of hepatocytic- and biliary-specific transcription factors in regenerating bile ducts during hepatocyte-to-biliary epithelial cell transdifferentiation. *Comp. Hepatol.* 2010, 9, 9. [CrossRef] [PubMed]

148. Berg, C.W.V.D.; Ritsma, L.; Avramut, M.C.; Wiersma, L.E.; Berg, B.M.V.D.; Leuning, D.G.; Lievers, E.; Koning, M.; Vanslambrouck, J.M.; Koster, A.J.; et al. Renal Subcapsular Transplantation of PSC-Derived Kidney Organoids Induces Neo-vasculogenesis and Significant Glomerular and Tubular Maturation In Vivo. *Stem Cell Rep.* 2018, 10, 751–765. [CrossRef]

149. An, M.C.; Zhang, N.; Scott, G.; Montoro, D.; Wittkop, T.; Mooney, S.; Melov, S.; Ellerby, L.M. Genetic Correction of Huntington’s Disease Phenotypes in Induced Pluripotent Stem Cells. *Cell Stem Cell* 2012, 9, 2558. [CrossRef] [PubMed]

150. Yusa, K.; Rashid, S.T.; Strick-Marchand, H.; Varela, I.; Liu, P.-Q.; Paschon, D.E.; Miranda, E.; Ordóñez, A.; Hannan, N.; Rouhani, F.J.; et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. *Nat. Cell Biol.* 2011, 478, 391–394. [CrossRef]

151. Zou, J.; Mali, P.; Huang, X.; Dowey, S.N.; Cheng, L. Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. *Blood* 2011, 118, 4599–4608. [CrossRef]

152. Fong, H.; Wang, C.; Knoferle, J.; Walker, D.; Balestra, M.E.; Tong, L.M.; Leung, L.; Ring, K.L.; Seeley, W.W.; Karydas, A.; et al. Genetic Correction of Tauopathy Phenotypes in Neurons Derived from Human Induced Pluripotent Stem Cells. *Stem Cell Rep.* 2013, 1, 226–234. [CrossRef]

153. Corti, S.; Nizzardo, M.; Simone, C.; Falcone, M.; Nardini, M.; Ronchi, D.; Donadoni, C.; Salani, S.; Riboldi, G.; Magri, F.; et al. Genetic Correction of Human Induced Pluripotent Stem Cells from Patients with Spinal Muscular Atrophy. *Sci. Transl. Med.* 2012, 4, 165ra162. [CrossRef]

154. Wang, Y.; Zheng, C.-G.; Jiang, Y.; Zhang, J.; Chen, J.; Yao, C.; Zhao, Q.; Liu, S.; Chen, K.; Du, J.; et al. Genetic correction of β-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. *Cell Res.* 2012, 22, 637–648. [CrossRef]

155. Ding, Q.; Lee, Y.-K.; Schaefer, E.; Peters, D.T.; Veres, A.; Kim, K.; Kupperwasser, N.; Motola, D.L.; Meissner, T.B.; Hendriks, W.T.; et al. A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models. *Cell Stem Cell* 2013, 12, 238–251. [CrossRef] [PubMed]

156. Liang, P.; Lan, F.; Lee, A.S.; Gong, T.; Sanchez-Freire, V.; Wang, Y.; Diecke, S.; Sallam, K.; Knowles, J.W.; Wang, P.J.; et al. Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity. *Circulation* 2013, 127, 1677–1691. [CrossRef]

157. Braam, S.; Tertoolen, L.; Casini, S.; Matsa, E.; Lu, H.; Teisman, A.; Passier, R.; Denning, C.; Gallacher, D.; Towart, R.; et al. Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. *Stem Cell Res.* 2013, 10, 48–56. [CrossRef] [PubMed]

158. Terrenoire, C.; Wang, K.; Tung, K.W.C.; Chung, W.K.; Pass, R.H.; Lu, J.T.; Jean, J.-C.; Omari, A.; Sampson, K.J.; Kotton, D.; et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. *J. Gen. Physiol.* 2012, 141, 61–72. [CrossRef] [PubMed]

159. Sharma, A.; Burridge, P.W.; McKeithan, W.L.; Serrano, R.; Shukla, P.; Sayed, N.; Churko, J.M.; Kitani, T.; Wu, H.; Holmström, A.; et al. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells. *Sci. Transl. Med.* 2017, 9, eaaf2584. [CrossRef]

160. Sharma, A.; Marceau, C.; Hamauchi, R.; Burridge, P.W.; Rajarajan, K.; Churko, J.M.; Wu, H.; Sallam, K.I.; Matsa, E.; Sturzu, A.C.; et al. Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform. *Circ. Res.* 2014, 115, 556–566. [CrossRef]